<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5347-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Soliris
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ECULIZUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15227.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Alexion Pharma International Operations Unlimited Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Alexion Pharma International Operations Unlimited Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Alexion Europe SAS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Soliris contains the active substance eculizumab and it belongs to a class of medicines called monoclonal antibodies. Eculizumab binds to and inhibits a specific protein in the body that causes inflammation and so prevents your body&rsquo;s systems from attacking and destroying vulnerable blood cells.</p><p dir="ltr">&nbsp;</p><p dir="ltr">What is SOLIRIS&reg; used for</p><ul dir="ltr"><li>Paroxysmal Nocturnal Haemoglobinuria (PNH):</li></ul><p dir="ltr">Soliris is used to treat adults and children patients with a certain type of disease affecting the blood system called Paroxysmal Nocturnal Haemoglobinuria (PNH). In patients with PNH, their red blood cells can be destroyed which can lead to low blood counts (anaemia), tiredness, difficulty in functioning, pain, dark urine, shortness of breath, and blood clots. Eculizumab can block the body&rsquo;s inflammatory response, and its ability to attack and destroy its own vulnerable PNH blood cells.</p><ul dir="ltr"><li>Atypical Haemolytic Uremic Syndrome (aHUS)</li></ul><p dir="ltr">Soliris is also used to treat adults and children patients with a certain type of disease affecting the blood system and kidney called atypical Haemolytic Uremic Syndrome (aHUS). In patients with aHUS, their kidney and blood cells, including platelets, can be inflamed which can lead to low blood counts (thrombocytopenia and anaemia), reduced or lost kidney function, blood clots, tiredness and difficulty in functioning. Eculizumab can block the body&rsquo;s inflammatory response, and its ability to attack and destroy its own vulnerable blood and kidney cells.</p><p dir="ltr">&nbsp;</p><ul dir="ltr"><li>Refractory Generalized Myasthenia Gravis(gMG)</li></ul><p dir="ltr">Soliris is also used to treat adult patients with a certain type of disease affecting the muscles and called generalized Myasthenia Gravis (gMG). In patients with gMG, their muscles can be attacked and damaged by the immune system which can lead to profound muscle weakness, impaired mobility, shortness of breath, extreme fatigue, risk for aspiration, and markedly impaired activities of daily living. Soliris can block the body&rsquo;s inflammatory response, and its ability to attack and destroy its own muscles to improve muscle contraction, thereby reducing symptoms of the disease and impact of the disease on the activities of daily living. Soliris is specifically indicated for patients who remain symptomatic despite treatment with other existing MG therapies.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not take Soliris&reg;</p><p dir="ltr">&nbsp;</p><ul dir="ltr"><li>If you are allergic to eculizumab, proteins derived from mouse products, other monoclonal antibodies, or any of the other ingredients of this medicine (listed in section 6).</li><li>If you have not been vaccinated against meningococcal infection unless you take antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated.</li><li>If you have a meningitis infection.</li></ul><p dir="ltr">&nbsp;</p><p dir="ltr">Do not take Soliris<sup>&reg; </sup></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to eculizumab, proteins derived from mouse products, other monoclonal antibodies, or any of the other ingredients of this medicine (listed in section 6).&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have not been vaccinated against meningococcal infection unless you take antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated.&nbsp;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a meningitis infection.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Warnings and precautions</p><p dir="ltr"><strong>Meningitis alert! </strong></p><p dir="ltr">Soliris treatment may reduce your natural resistance to infections, especially against certain organisms that cause meningitis (infection of the linings of the brain).</p><p dir="ltr">Consult your doctor before you take Soliris to be sure that you receive vaccination against <em>Neisseria meningitidis</em>, an organism that causes meningitis, at least 2 weeks before beginning therapy, or that you take antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated. Ensure that your current meningitis vaccination is up to date. You should also be aware that vaccination may not prevent this type of infection</p><p dir="ltr">In accordance with national recommendations, your doctor may consider that additional measures are needed to prevent infection. &nbsp;</p><p dir="ltr"><strong><u>Meningitis symptoms</u>&nbsp; </strong></p><p dir="ltr">Because of the importance of rapidly identifying and treating certain types of infection in patients who receive Soliris, you will be provided a card to carry with you, listing specific trigger symptoms. This card is named: &ldquo;Patient Safety Card&rdquo;.</p><p dir="ltr"><strong>If you experience any of the following symptoms, you should immediately inform your doctor:&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache with nausea or vomiting;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache with a stiff neck or back;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe muscle aches combined with flu-like symptoms;</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light</p><p dir="ltr">Treatment for meningitis while travelling&nbsp;</p><p dir="ltr">If you are travelling in a remote region where you are unable to contact your doctor or in which you find yourself temporarily unable to receive medical treatment, your doctor can make arrangements to issue, as a preventive measure, a prescription for an antibiotic that you keep with you to counter Neisseria meningitidis. If you experience any of the symptoms amongst those cited above, you should take the antibiotics as prescribed. You should bear in mind that you should see a doctor as soon as possible, even if you feel better after having taken the antibiotics.</p><p dir="ltr"><strong>Infections </strong>&nbsp;</p><p dir="ltr">Before starting Soliris, inform your doctor if you have any infections.&nbsp;</p><p dir="ltr"><strong>Allergic reactions </strong></p><p dir="ltr">Soliris contains a protein, and proteins can cause allergic reactions in some people.</p><p dir="ltr">Soliris<sup>&reg; </sup>in<sup> </sup>children and adolescents</p><p dir="ltr">Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections.</p><p dir="ltr">Soliris<sup>&reg; </sup>in older people</p><p dir="ltr">There are no special precautions needed for the treatment of patients aged from 65 years and over.&nbsp;</p><p dir="ltr">Soliris<sup>&reg;</sup> with other medicines</p><p dir="ltr">Tell your doctor or pharmacist if you are using or have recently used or might use any other medicines Including medicines obtained without a prescription.</p><p dir="ltr">Pregnancy, breast feeding&nbsp;</p><p dir="ltr"><u>Pregnancy/ breast-feeding</u> &nbsp;</p><p dir="ltr">If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.<strong> </strong>&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Women of childbearing potential</u></p><p dir="ltr">The use of effective contraception during treatment and up to 5 months after treatment should be considered in women who are able to get pregnant.</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">Soliris has no or negligible influence on the ability to drive and use machines.&nbsp;</p><p dir="ltr">Soliris<sup>&reg; </sup>contains sodium</p><p dir="ltr">Soliris contains 115 mg<strong> </strong>of sodium in one 30 ml vial. This should be taken into consideration in patients who are on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">At least 2 weeks before you start treatment with Soliris, your doctor will administer a vaccine against meningitis if it was not previously administered or if your vaccination is outdated. If your child is below the age of vaccination or if you are not vaccinated at least 2 weeks before you start treatment with Soliris, your doctor will prescribe antibiotics to reduce the risk of infection until 2 weeks after you have been vaccinated.&nbsp;</p><p dir="ltr">Your doctor will administer a vaccine to your child aged less than 18 years against <em>Haemophilus influenzae</em> and pneumococcal infections according to the national vaccination recommendations for each age group.&nbsp;</p><p dir="ltr">Instructions for proper use</p><p dir="ltr">The treatment will be given by your doctor or other health care provider by infusing a dilution of the Soliris vial from a drip bag through a tube directly into one of your veins over 25 &ndash; 45 minutes in adult patients and over 1 to 4 hours in paediatric patients. Following each infusion, you will be monitored for about one hour. Your doctor&rsquo;s instructions should be carefully observed.</p><p dir="ltr">It is recommended that the beginning of your treatments, called the initial phase, will extend over 4 weeks, followed by a maintenance phase.</p><p dir="ltr"><strong>Recommended Dose Regimen I.</strong><strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong><u>For adult patients:</u> </strong></p><p dir="ltr">To treat PNH&nbsp;</p><p dir="ltr"><strong>Initial Phase: </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every week for the first four weeks, your doctor will administer an intravenous infusion of diluted Soliris. Each infusion will consist of a dose of 600 mg (2 vials of 30 ml) and will take 25-45 minutes.</p><p dir="ltr"><strong>Maintenance Phase: </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the fifth week, your doctor will administer an intravenous infusion of diluted Soliris at a dose of 900 mg (3 vials of 30 ml)&nbsp; over 25-45 minutes.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the fifth week, your doctor will administer 900 mg of diluted Soliris every two weeks as a long-term treatment.</p><p dir="ltr"><strong>To treat aHUS or gMG:</strong></p><p dir="ltr"><strong>Initial Phase: </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Every week for the first four weeks, your doctor will administer an intravenous infusion of diluted Soliris. Each infusion will consist of a dose of 900 mg (3 vials of 30 ml) and will take 25-45 minutes.</p><p dir="ltr"><strong>Maintenance Phase: </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the fifth week, your doctor will administer an intravenous infusion of diluted Soliris at a dose of 1,200 mg (4 vials of 30 ml) over a 25 &ndash; 45-minute period.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After the fifth week, your doctor will administer 1,200 mg of diluted Soliris every two weeks as a long-term treatment.</p><p dir="ltr"><strong>II.</strong><strong> &nbsp;&nbsp;&nbsp;&nbsp; <u>For children and adolescents who are less than 18 years of age:</u></strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents with PNH or aHUS and who are 40 kg weight and over are treated with the adult dosing.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children and adolescents with PNH or aHUS and who are under 40 kg weight require a lower dose based on how much they weigh. Your doctor will calculate this.</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>Body Weight&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Initial Phase&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Maintenance Phase&nbsp; </strong></p></td></tr><tr><td style="vertical-align:top"><p>30 to &lt;40 kg&nbsp;</p></td><td style="vertical-align:top"><p>600 mg weekly x 2&nbsp;</p></td><td style="vertical-align:top"><p>900 mg at week 3; then 900 mg every</p><p>2 weeks&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>20 to &lt;30 kg&nbsp;</p></td><td style="vertical-align:top"><p>600 mg weekly x 2&nbsp;</p></td><td style="vertical-align:top"><p>600 mg at week 3; then 600 mg every 2 weeks&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>10 to &lt;20 kg&nbsp;</p></td><td style="vertical-align:top"><p>600 mg weekly x 1&nbsp;</p></td><td style="vertical-align:top"><p>300 mg at week 2; then 300 mg every 2 weeks&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>5 to &lt;10 kg&nbsp;</p></td><td style="vertical-align:top"><p>300 mg weekly x 1&nbsp;</p></td><td style="vertical-align:top"><p>300 mg at week 2; then 300 mg every 3 weeks&nbsp;</p></td></tr></tbody></table><p dir="ltr">Patients who undergo plasma exchange (PE)/plasma infusion (PI) require additional doses of Soliris.</p><p dir="ltr">If you are administered more Soliris<sup>&reg;</sup> than you should receive</p><p dir="ltr">If you suspect that you have been accidentally administered a higher dose of Soliris than prescribed, please contact your doctor for advice.</p><p dir="ltr">If you forget an appointment to be treated with SOLIRIS<sup>&reg;</sup></p><p dir="ltr">If you forget an appointment, please contact your doctor immediately for advice and see section below &ldquo;If you stop taking Soliris&rdquo;.</p><p dir="ltr">If you stop taking Soliris<sup>&reg;&nbsp; </sup></p><p dir="ltr">Do not stop receiving Soliris without first talking to your doctor. <strong>&nbsp;</strong></p><p dir="ltr"><strong>If you stop using Soliris for PNH: </strong></p><p dir="ltr">Interrupting or ending treatment with Soliris may cause your PNH symptoms to come back more severely soon. Your doctor will discuss the possible side effects with you and explain the risks.&nbsp; Your doctor will want to continue to monitor you closely for at least 8 weeks.</p><p dir="ltr"><strong>The risks of stopping Soliris include an increase in the destruction of your red blood cells, which may cause: </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A significant fall in your red blood cell counts (anaemia),&nbsp;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion or change in how alert you are,&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, or angina,&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in your serum creatinine level (problems with your kidneys), or&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombosis (blood clotting).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">If you have any of these symptoms, contact your doctor.</p><p dir="ltr">If you stop using Soliris for aHUS</p><p dir="ltr">Interrupting or ending treatment with Soliris may cause your aHUS symptoms to come back. Your doctor will discuss the possible side effects with you and explain the risks. Your doctor will want to monitor you closely.</p><p dir="ltr">The risks of stopping Soliris include an increase in the inflammation of your platelets, which may cause:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A significant fall in your platelets (thrombocytopenia),&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A significant rise in destruction of your red blood cells,&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased urination (problems with your kidneys),&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in your serum creatinine level (problems with your kidneys),&nbsp;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Confusion or change in how alert you are,&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, or angina,&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, or&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombosis (blood clotting).&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="ltr">If you have any of these symptoms, contact your doctor.</p><p dir="ltr">If you stop using Soliris for refractory gMG</p><p dir="ltr">Interrupting or stopping treatment with Soliris may cause your gMG symptoms to come back. Please speak to your doctor before stopping Soliris. Your doctor will discuss the possible side effects and risks with you. Your doctor will also want to monitor you closely.</p><p dir="ltr">If you have any further questions on the use of this product, ask your doctor or pharmacist.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss the possible side effects with you and explain the risks and benefits of Soliris with you prior to treatment.</p><p dir="ltr">The most serious side effect is meningococcal infection.</p><p dir="ltr">If you experience any of the meningitis symptoms (see section 2 &ldquo;Meningitis alert&rdquo;), you should immediately inform your doctor.</p><p dir="ltr">If you are not sure what the side effects below are, ask your doctor to explain them to you.</p><p dir="ltr"><strong>Very common side effects (may affect more than 1 in every 10 patients): </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache;</p><p dir="ltr"><strong>Common side effects</strong> <strong>(may affect up to 1 in 10 patients): </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the lung (pneumonia), common cold (nasopharyngitis), infection of the urinary system (urinary tract infection);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell count (leukopenia);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, taste disorders (dysgeusia), shaking;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection, cough, throat pain (oropharyngeal pain);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea, vomiting, nausea, abdominal pain;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, hair loss (alopecia), itchy skin (pruritus);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the limbs or joints (arms and legs);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (pyrexia), chills, feeling tired (fatigue), influenza like illness.</p><p dir="ltr"><strong>Uncommon side effects</strong> <strong>(may affect up to 1 in 100 patients):</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infection: (meningococcal infection), sepsis, septic shock, viral infection, bronchitis, cold sores (herpes simplex), lower respiratory tract infection, stomach flu (gastrointestinal infection), cystitis;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other infections: fungal infection, collection of pus (abscess), cellulitis (skin infection), influenza, sinusitis, tooth infection;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; relatively few platelets in blood (thrombocytopenia), low level of lymphocytes {a specific type of white blood cells (lymphopenia)}, feeling your heart beat;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reaction which causes difficulty in breathing or dizziness (anaphylactic reaction), hypersensitivity;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression, anxiety, mood changes;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling in some parts of the body (paresthesia);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears, vertigo;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden and rapid development of extremely high blood pressure, low blood pressure, hot flush, vein disorder;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dyspnoea (difficulty breathing), nose bleed, stuffy nose (nasal congestion), throat irritation, runny nose;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the peritoneum (the tissue that lines most of the organs of the abdomen), constipation, stomach discomfort after meals (dyspepsia), abdominal distension;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives, redness of the skin, dry skin, red or purple spots under the skin, increased sweating;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramp, muscle aches, back and neck pain, bone pain, joint swelling;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney disorder, difficulties or pain when urinating;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous penile erection;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling (edema), chest discomfort, feeling of weakness (asthenia), chest pain, infusion site pain;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of liver enzymes, decrease of the proportion of blood volume that is occupied by red blood cells, decrease in the protein in red blood cells that carries oxygen.</p><p dir="ltr"><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection by fungi (Aspergillus infection), infection of the joint (bacterial arthritis), Haemophilus influenzae infection, gum infection, impetigo, bacterial sexual transmitted disease;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin tumor (melanoma), bone marrow disorder;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; destruction of red blood cells (haemolysis), clumping of cells, abnormal clotting factor, abnormal blood clotting;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disease with thyroid overactivity (Basedow&rsquo;s disease);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disorder, abnormal dreams;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation of eyes;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruises;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual backflow of food from stomach, gum pain;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and/or eyes (jaundice);</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin, skin colour disorder;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spasm of mouth muscle;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in urine;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual disorder;&nbsp;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal leakage of the infused drug out of the vein, infusion site abnormal sensation, feeling hot;</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infusion related reactions.</p><p dir="ltr">If you experience any of these side effects, or if you observe any side effect not listed in this leaflet, please inform your doctor immediately.</p><p dir="ltr">Reporting of adverse effects</p><p dir="ltr">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA&rdquo; By reporting side effects, you can help provide more information on the safety of this medicine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2<sup>&deg;</sup>C &ndash; 8<sup>&deg;</sup> C) in its original package in order to protect from light.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not shake.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliris vials in the original package may be removed from refrigerated storage <strong>for only one single period of up to 3 days.</strong> At the end of this period the product can be put back in the refrigerator.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diluted solutions of Soliris may be stored at 2<sup></sup>C - 8<sup></sup>C for up to 24 hours prior to administration.</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Each vial contains<strong> the active substance: </strong>&nbsp;eculizumab 300 mg/30ml (corresponding to 10mg/ml)</p><p dir="ltr"><strong>The other ingredients are: </strong></p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium phosphate monobasic</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium phosphate dibasic</p><p dir="ltr">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sodium chloride</p><p dir="ltr">polysorbate 80 (vegetable origin) <strong>Solvent: w</strong>ater for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Soliris is presented as a concentrate for solution for infusion. It is a clear, colorless, preservative free solution supplied in a box containing one 30 ml single-use vial. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorisation Holder: </strong></p><p dir="ltr">Alexion Europe SAS</p><p dir="ltr">1-15, avenue Edouard Belin&nbsp;</p><p dir="ltr">92500 Rueil-Malmaison</p><p dir="ltr">France</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Manufacturer: </strong></p><p dir="ltr">Alexion Pharma International Operations Unlimited Company</p><p dir="ltr">College Business and Technology Park</p><p dir="ltr">Blanchardstown</p><p dir="ltr">Dublin 15</p><p dir="ltr">Ireland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved on 12/2017 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو سوليريس </strong></p><p dir="RTL">يحتوي سوليريس على المادة الفعالة إيكوليزوماب وينتمي إلى فئة من الأدوية&nbsp; تُسمّى الأجسام المُضادة وحيدة النسيلة. يرتبط إيكوليزوماب ببروتين معين في الجسم يسبب الالتهاب ويؤدي إلى تثبيطه وبالتالي يمنع أنظمة الجسم من مهاجمة خلايا الدّم الضعيفة وتدميرها.<strong> </strong></p><p dir="RTL">&nbsp;<strong>دواعي استخدام سوليريس</strong></p><p dir="RTL"><strong>&nbsp;البِيلة الهيموغلوبينيّة الليليّة الإنتيابية: </strong><strong>&nbsp;: Paroxysmal Nocturnal Hemoglobinuria (PNH)</strong></p><p dir="RTL">يستخدم سوليريس لعلاج المرضى البالغين والأطفال الذين يعانون من نوع معين من الأمراض يُؤثر على جهاز الدّم ويُسمّى البِيلة الهيموغلوبينيّة الليليّة الإنتيابية<strong> </strong><strong>(PNH)</strong>. يمكن أن يحدث تدمير لخلايا الدّم الحمراء لدى المرضى الذين يعانون من PNH، ممّا&nbsp; يُؤدي إلى:</p><p dir="RTL">&nbsp;انخفاض تعداد خلايا الدّم (فقر الدّم) ، والتعب، وصعوبة في أداء العمل، والألم، والبول الداكن، وضيق في التنفس، وجلطات الدّم.</p><p dir="RTL">يمكن لسوليريس منع الاستجابة الالتهابية للجسم، وبالتالي منعه من مهاجمة وتدمير خلايا الدّم الضعيفة في المُصابين بهذا المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متلازمة انحلال الدّم اليوريميّ اللانموذجية (</strong><strong>aHUS</strong><strong>) </strong></p><p dir="RTL">يستخدم سوليريس أيضًا لعلاج المرضى البالغين والأطفال الذين يعانون من نوع معين من الامراض التي&nbsp; تُؤثر على نظام الدم والكِلى يسمي متلازمة انحلال الدّم اليوريميّ اللانموذجية <strong>(</strong><strong>aHUS</strong><strong>)</strong>.</p><p dir="RTL">يُمكن أن يحدث لدى المرضى المُصابين بمتلازمة انحلال الدّم اليوريميّ اللانموذجيّة aHUS التهاب للكِلى وخلايا الدّم بما في ذلك الصفائح الدّموية مما يُؤدي إلى:</p><p dir="RTL">انخفاض في عدد الصفائح الدّموية، اختلال وظائف الكِ لى أو فشل كلوي نهائي، جلطات دمويّة، التعب وصعوبة في الأداء.</p><p dir="RTL">&nbsp;يُمكن لسوليريس منع الاستجابة الالتهابية للجسم وقدرته على مهاجمة وإتلاف خلايا الدّم والكِ لى في الشخص المريض.</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;:{generalized Myasthenia Gravis (gMG)} </strong>الوهن العضلي الوبيل المُعمّم</p><p dir="RTL">&nbsp;يُستخدم سوليريس أيضًا لعلاج المرضى البالغين المُصابين بنوع معين من الامراض يُؤثر على العضلات ويدعى الوهن العضلي الوبيل المُعمّم <strong>(gMG)</strong>.&nbsp; يقوم الجهاز المناعي عند مرضى gMG بمهاجمة العضلات وتدميرها مما ي يُؤدّي إلى:</p><p dir="RTL">ضعف شديد في العضلات، ضعف الحركة، ضيق في التنفس، التعب الشديد، وخطر حدوث الاستنشاق الرئوي وتدهور كبير في أنشطة الحياة اليومية. يمكن لسوليريس حجب الاستجابة الالتهابية للجسم، وقدرته على مهاجمة وتدمير عضلاته لتحسين تقلص العضلات، وبالتالي تقليل أعراض المرض وتأثيره على أنشطة الحياة اليومية. يُستخدم سوليريس على وجه التحديد للمرضى الذين لا تزال لديهم أعراض للمرض على الرغم من علاجهم بالعلاجات الأخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;لا تتناول سوليريس: </strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من حساسية تجاه إيكوليزوماب أو البروتينات المشتقة من الفئ ارن، أو تجاه الأجسام المضادة وحيدة النسيلة الأخرى، أو أيّ من المكونات الأخرى لهذا الدواء )المذكورة في الفقرة 6(.<strong> </strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا لم يتم تطعيمك ضد عدوى المكوارت السّحائية إلّا إذا تلقيت العلاج الوقائي بالمُضادات الحيوية المُناسبة لمدّة أسبوعين بعد التطعيم.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مُصاباً بعدوى التهاب السّحايا.</p><p dir="RTL"><strong>المحاذير والاحتياطات </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:756px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>تنبيه التهاب السحايا! </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">قد يُقلل العلاج بسوليريس من مقاومتك الطبيعية للإصابة بالعدوى، خاصة ضد بعض الكائنات الحية التي</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تسبب عدوى التهاب السّحايا(عدوى الأغشية المُبطّنة للدّماغ).</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">استشر طبيبك قبل تلقي العلاج بسوليريس للتأكد من أنّ تطعيمك الحالي ضد التهاب السّحايا لا يزال ساري المفعول وإلّا فإنّه يجب عليك التطعيم بلقاح ضد المُكوّارت النيسرية السّحائيّة المُسببة لالتهاب السحايا وذلك قبل بدء العلاج بمدة أسبوعين على الأقل أو استخدام مضادات حيوية لمدة أسبوعين بعد التطعيم للحد من خطر الإصابة بالعدو ى، يجب أن تكون على علم أيضاً بأنّ هذا التطعيم قد لا يمنع كُل أنواع عدوى التهاب السّحايا.&nbsp;</p><p dir="RTL">وفقاً للتّوصيات الوطنية، فإن طبيبك قد يعتبر أنّ هناك حاجة إلى تدابير إضافية للوقاية من العدوى.</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض التهاب السحايا </strong></p><p dir="RTL">بسبب أهمية تحديد ومعالجة أنواع معينة من العدوى بسرعة لدى المرضى الذين يتلقون العلاج بسوليريس فإنّه سوف يتم تزويدك ببطاقة لتكون معك دائماً، تحتوي على قائمة لأعراض مُحدّدة مُثيرة للمرض.&nbsp; تُسمّى هذه البطاقة باسم: &quot;بطاقة سلامة المريض&quot;.</p><p dir="RTL"><strong>عليك إبلاغ طبيبك فواًر إذا واجهت أيّاً من الأعارض التالية: </strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>صداع مع الغثيان أو القيء؛</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>صداع مع تصلب في العنق أو الظهر؛</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>حُمّى</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>طفح جلدي؛</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>الارتباك؛</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>آلام عضلية شديدة مصحوبة بأعراض تشبه أعراض الأنفلونزا؛</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp; </strong>الحساسية للضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>علاج التهاب السحايا أثناء السفر </strong></p><p dir="RTL">إذا كنت تنوي السفر إلى منطقة بعيدة حيث لا يمكنك الاتصال بطبيبك أو حيث قد تجد نفسك عاجزا مؤقتا عن تلقي العلاج الطبي، فإنّه يمكن لطبيبك اتخاذ الترتيبات اللازمة لإصدار وصفة طبية لمضاد حيو ي يُمكنك الاحتفاظ به معك كعلاج وقائي لمواجهة المُكوّارت النيسرية السّحائيّة. وفي حال عانيت من أيّ من الأعراض المذكورة أعلاه، فيجب أن تتناول المُضاد الحيوي كما هو موصوف لك. كما يجب أن تضع في&nbsp; اعتبارك أنك يجب أن تراجع الطبيب في أقرب وقت ممكن حتى وإن كنت تشعر بتحسُّن بعد تناولك المُضاد الحيوي.</p><p dir="RTL"><strong>العدوى </strong></p><p dir="RTL">أبلغ طبيبك إذا كان لديك أيّ عدوى قبل بدء العلاج بسوليريس.<strong> </strong></p><p dir="RTL"><strong>ردود الفعل التحسسية </strong></p><p dir="RTL">يحتوي سوليريس على بروتين، وقد تسبب البروتينات ردود فعل تحسّسيّة لدى بعض الأفراد.</p><p dir="RTL"><strong>سوليريس والأطفال والمراهقون </strong></p><p dir="RTL">يجب تطعيم المرضى الذين تقل أعمارهم عن 18 عامًا ضد عدوى والتهاب المكوارت الرئوية و المُستدمية النزلية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>سوليريس وكبار السن </strong></p><p dir="RTL">لا توجد احتياطات خاصة لعلاج المرضى الذين تتراوح أعمارهم بين 65 سنة وما فوق.</p><p dir="RTL"><strong>سوليريس مع الأدوية الأخر ى </strong></p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرا أو إذا كنت ستستخدم أيّ أدوية أخرى بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL"><strong>&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية&nbsp; </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>الحمل/الرضاعة الطبيعية</u></p><p dir="RTL">استشيري طبيبك قبل البدء في العلاج بسوليريس إذا كنتِ حاملاً أو مُرضعة، تعتقدين أنّك قد تكونين حاملاً أو تخططين للحمل.</p><p dir="RTL"><u>النساء في سن الإنجاب:</u><strong>&nbsp; </strong></p><p dir="RTL">يجب أن تستخدم أيّ امرأة يمكنها الإنجاب وسائل فعّالة لمنع الحمل أثناء العلاج بسوليريس ولمدة 5 شهور بعد انتهاء العلاج.</p><p dir="RTL"><strong>القيادة واستخدام الآلات: </strong></p><p dir="RTL">ليس لسوليريس أيّ&nbsp; تأثير يذكر على القدرة على القيادة واستخدام الآلات .</p><p dir="RTL"><strong>سوليريس يحتوي على الصوديوم&nbsp; </strong></p><p dir="RTL">يحتوي سوليريس على 115 مجم من الصوديوم في القارورة الواحدة سعة 30 مل. لذا ينبغي مراعاة ذلك لدى المرضى الذين يتبعون نظاماً غذائيّاً قليل الصوديوم.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم طبيبك قبل 14 يوماً على الأقل من بدء العلاج بسوليريس، بإعطائك تطعيماً ضد عدوى التهاب السّحايا إذا لم يكن قد تم إعطاؤه لك سابقاً أو إذا كان تطعيمك قديماً.</p><p dir="RTL">إذا كان عُمر طفلك أقل من عمر التطعيم أو إذا لم يتم تطعيمك قبل أسبوعين على الأقل من بدء العلاج&nbsp; بسوليريس، فسيقوم الطبيب بوصف المضادات الحيوية لتقليل خطر العدوى لمدة أسبوعين بعد التطعيم. سيقوم طبيبك بإعطاء لقاح لطفلك الذي يقل عمره عن 18 عامًا ضد المُستدمية النزلية والتهاب المكوارت الرئوية وفقًا لتوصيات التطعيم المحليّة لكل فئة عمرية.</p><p dir="RTL"><strong>تعليمات للاستخدام الصحيح&nbsp; </strong></p><p dir="RTL">سيتم إعطاءك العلاج من قبل طبيبك أو مُقدِّم رعاية صحية آخر عن طريق تخفيف مُركّز سوليريس بإضافته&nbsp; إلى كيس للحقن ومن ثمّ حقنه بالتسريب الوريدي من خلال أنبوب متصل مباشرة بأحد الأوردة لديك على مدى 25-45 دقيقة &quot;للبالغين&quot; و 1-4 ساعة &quot;للأطفال&quot;.&nbsp;</p><p dir="RTL">يوصى بأن تمتد بداية العلاج الخاص بك، والتي&nbsp; تُسمّى المرحلة الأوليّة، على مدى 4 أسابيع، تليها المرحلة المُستمرة.</p><p dir="RTL">نظام الجرعة المُوصى بها I.<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong><u>المرضى البالغين</u></strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;لعلاج</strong><strong> البِيلة الهيموغلوبينيّة الليليّة الإنتيابية (</strong><strong>PNH</strong><strong>):</strong><strong> </strong></p><p dir="RTL"><strong>المرحلة الأ ولية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم الطبيب في كل أسبوع من الأسابيع الأربعة الأولى بحقنك بتسريب وريدي من سوليريس المخفف .</p><p dir="RTL">ويتكون كل تسريب من جرعة من 600 مجم( 2 قارورة سعة كل منها 30 مل) على مدى 25-45 دقيقة.</p><p dir="RTL"><strong>المرحلة المُستمرة: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في الأسبوع الخامس، سيقوم الطبيب بحقنك بتسريب وريدي من سوليريس المخفف مكون من جرعة من900 مجم (3 قوارير سعة كل منها 30 مل) على مدى 25-45 دقيقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الأسبوع الخامس، سيقوم الطبيب بإعطائك 900 مجم من سوليريس المخفف كل أسبوعين كعلاج طويل الأمد.</p><p dir="RTL"><strong>لعلاج </strong><strong>متلازمة انحلال الدّم اليوريميّ اللانموذجيّة (</strong><strong> </strong><strong>(</strong><strong>aHUS</strong><strong>أو </strong><strong>الوهن العضلي الوبيل المُعمّم (</strong><strong>gMG</strong><strong>)</strong><strong>:</strong><strong> </strong></p><p dir="RTL"><strong>المرحلة الأولية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم الطبيب في كل أسبوع من الأسابيع الأربعة الأولى بحقنك بتسريب وريدي من سوليريس المخفف</p><p dir="RTL">ويتكون كل تسريب من جرعة من 900 مجم (3 قارورة سعة كل منها 30 مل) على مدى 25-45 دقيقة.</p><p dir="RTL"><strong>المرحلة المُستمرة: </strong></p><p dir="RTL">في الأسبوع الخامس، سيقوم الطبيب بحقنك بتسريب وريدي من سوليريس المخفف مكون من جرعة 1200 مجم (4 قوارير سعة كل منها 30 مل) على مدى 25-45 دقيقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الأسبوع الخامس، سيقوم الطبيب بإعطائك 1200 مجم من سوليريس المخفف كل أسبوعين كعلاج طويل الأمد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>II</strong><strong>.</strong><strong>&nbsp;&nbsp; </strong><strong><u>الأطفال والمراهقون أقل من 18 عاماً</u></strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم علاج الأطفال والمراهقين الذين يعانون من PNH &nbsp;أو aHUS ممن تبلغ اوزانهم 40 كجم وما فوق بنفس جرعة البالغين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتاج الأطفال والمراهقون الذين يعانون من PNH أو aHUS والذين تقل أوزانهم عن 40 كجم إلى جرعة أقل بناءاً على وزنهم. سيقوم طبيبك بحساب الجرعة.&nbsp;</p><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:709px"><tbody><tr><td><p dir="RTL"><strong>المرحلة المُستمرة </strong></p></td><td><p dir="RTL"><strong>المرحلة الأوليّة </strong></p></td><td><p dir="RTL"><strong>وزن الجسم </strong></p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">900 مجم في الأسبوع الثالث 900 &nbsp;مجم كل أسبوعين</p></td><td style="vertical-align:top"><p dir="RTL">600 مجم كل أسبوع x 2<strong> </strong></p></td><td style="vertical-align:top"><p dir="RTL">30 كجم إلى أقل من 40 كجم</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">600 مجم في الأسبوع الثالث ثم 600 مجم كل أسبوعين</p></td><td style="vertical-align:top"><p dir="RTL">600 مجم كل أسبوع x 2<strong> </strong></p></td><td style="vertical-align:top"><p dir="RTL">20 كجم إلى أقل من 30 كجم</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">300 مجم في الأسبوع الثاني ثم 300 &nbsp;&nbsp;مجم كل أسبوعين</p></td><td style="vertical-align:top"><p dir="RTL">600 مجم كل أسبوع x 1<strong> </strong></p></td><td style="vertical-align:top"><p dir="RTL">10 كجم إلى أقل من 20 كجم</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL">300 مجم في الأسبوع الثاني 300 &nbsp;مجم كل 3 أسابيع</p></td><td style="vertical-align:top"><p dir="RTL">300 مجم كل أسبوع x 1</p></td><td style="vertical-align:top"><p dir="RTL">5 كجم إلى أقل من 10 كجم</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">يحتاج المرضى الذين يخضعون لجلسات تبادل البلازما/ أو حقن البلازما بالتسريب إلى جرعات إضافية من سوليريس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تمّ إعطاؤك سوليريس أكثر مما يجب </strong></p><p dir="RTL">اتصل بطبيبك للمشورة إذا كنت تعتقد أنّه قد تمّ إعطاؤك<strong> </strong>سوليريس أكثر ممّا ينبغي.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت موعداً لتلقّي العلاج بسوليريس </strong></p><p dir="RTL">يُرجى الاتصال بالطبيب فورا &nbsp;للحصول على المشورة في حال نسيت موعداً. كما يُرجى الاطلاع على القسم أدناه &quot;إذا توقفت عن تناول سوليريس&quot;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن العلاج بسوليريس </strong></p><p dir="RTL">لا تتوقف عن العلاج بسوليريس دون التحدث مع طبيبك. <strong>&nbsp;</strong></p><p dir="RTL"><strong>التوقف عن العلاج لدى مرضى </strong><strong>PNH</strong><strong> </strong></p><p dir="RTL">قد يؤدي انقطاع أو إنهاء العلاج بسوليريس إلى ظهور أعراض PNH بشكل أكثر شدة في وقت قريب .</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يناقش طبيبك الأعراض الجانبية المحتملة معك ويشرح لك المخاطر .قد يود طبيبك أن يخضعك للمُراقبة عن كثب لمُدّة 1 أسابيع على الأقل.</p><p dir="RTL"><strong>تشمل مخاطر إيقاف سوليريس زيادة في تدمير خلايا الدّم الحمارء في مرضى </strong><strong>PNH </strong><strong>&nbsp;مما قد يؤدي إلى الأعارض التالية: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مُفاجئ أو حاد في عدد خلايا الدّم الحم ارء مما يُسبّب فقر الدّم (الأنيميا)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك أو تغيّر في مدى يقظتك؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصّدر/الذبحة الصّدرية؛&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى الكرياتين في الدّم(مشاكل في الِكلى)؛ أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدّم(تخثر الدّم).</p><p dir="RTL">ارجع طبيبك إذا كان لديك أيّ من هذه الأعراض.</p><p dir="RTL"><strong>التوقف عن العلاج لدى مرضى </strong><strong>aHUS</strong><strong>&nbsp; </strong></p><p dir="RTL">قد يؤدي انقطاع أو إنهاء العلاج بسوليريس إلى ظهور أع ارض aHUS مرة أخرى. سوف يناقش طبيبك الأعراض الجانبية المحتملة معك ويشرح لك المخاطر. قد يرغب طبيبك في مراقبتك عن كثب.</p><p dir="RTL"><strong>تشمل مخاطر إيقاف سوليريس زيادة في التهاب الصفائح الدّمويّة، مما يُؤدّي إلى الأعارض التالية: </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدّمو يّة؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ملحوظ في تدمير خلايا الدّم الحم ارء؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض التبول (مشاكل في الِكلى)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى الكرياتينين في الدّم(مشاكل في الِكلى)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك أو التغيير في مدى انتباهك؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، أو الذبحة الصدرية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس؛ أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلط الدّم.</p><p dir="RTL">ارجع طبيبك إذا كان لديك أيّ من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن العلاج لدى مرضى </strong><strong>gMG</strong><strong> </strong></p><p dir="RTL">قد يؤدي انقطاع أو إنهاء العلاج بسوليريس إلى ظهور أعراض gMG مرةً أخرى. استشر طبيبك قبل التوقف عن العلاج بسوليريس. سوف يناقش طبيبك الأعراض الجانبية المحتملة معك ويشرح لك المخاطر. قد يود طبيبك أن يُخضعك للمُراقبة عن كثب<strong>. </strong></p><p dir="RTL">اسأل طبيبك أو الصيدلي إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع جميع الأدوية، يُمكن أن يُسبّب هذا الدّواء أعراضاً جانبية، مع أنها لا تحدث لدى جميع المرضى. سوف يناقش طبيبك الأعراض الجانبية المحتملة معك ويشرح لك مخاطر وفوائد سوليريس قبل بدء العلاج.</p><p dir="RTL">أكثر الأعراض الجانبية خطورةً هو عدوى التهاب السّحايا.</p><p dir="RTL">إذا واجهت أيّاً من أعراض عدوى التهاب السّحايا (انظر القسم 2 &quot;تنبيه! التهاب السحايا)&quot; فيجب عليك إبلاغ طبيبك على الفور.</p><p dir="RTL">إذا لم تكن على دراية بالأعراض الجانبية التالية، فاطلب من طبيبك أن يشرحها لك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية شائعة جداً (من المحتمل أن تُصيب أكثر من 1 من كل</strong><strong> </strong><strong>10 مرضى): </strong>&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض الجانبية الشائعة ( قد تؤثر على ما يصل إلى 1 من كل 10 مرضى) : &nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئتين (الالتهاب الرئوي)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزلات البرد (التهاب البلعوم الأنفي)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز البولي (عدوى المسالك البولية)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدّم البيضاء (الكريات البيضاء)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدّم الحمراء مما يؤدّي إلى شحوب البشرة، ضعف أو ضيق في التنفس؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، اضطرابات في التذوق، الشعور بالارتجاج؛ &nbsp; &nbsp;&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدّم؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي العلوي، والسعال، وآلام الحلق (ألم فموي بلعومي)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، والتقيؤ، والغثيان، وآلام في البطن؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، تساقط الشعر )الصلع(، حكة في الجلد؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الأطراف أو المفاصل (الذراعين والساقين)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحُمّى، القشعريرة، الشعور بالتعب (الإرهاق)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض شبيه بالإنفلونزا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية غير شائعة(قد تؤثر على ما يصل إلى 1 من كل 100 مريض): &nbsp;&nbsp;</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة: (عدوى بالمكوارت السحائية)، تعفن الدّم، صدمة إنتانية، عدوى فيروسية، التهاب الشعب الهوائية، الهربِس البسيط (عدوى فيروسية)، عدوى الجهاز التنفسي السفلي، عدوى معوية، التهاب المثانة؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أنواع أخرى من العدوى: عدو ى بالفطريات، تجمع القيح(الخراج)، التهاب النسيج الخلوي نوع من العدوى في الجلد( الأنفلونزا، التهاب الجيوب الأنفية، عدوى الأسنان؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الصفائح الدّمويّة نسبيّاً، وانخفاض مستوى الخلايا الليمفاوية(نوع معين من خلايا الدّم البيضاء)، الخفقان؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل تحسسي خطير يُسبّب صعوبة في التنفس أو الدوخة )تفاعل تأقّي(، فرط الحساسية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب والقلق وتقلب المزاج؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالوخز في أجزاء من الجسم (تنميل)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح في الرؤية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رنين في الأذنين، الدُّوار؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التطور المفاجئ والسريع لضغط الدّم المرتفع، انخفاض ضغط الدّم، هبات ساخنة، اضطرابات الأوردة؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (صعوبة في التنفس)، نزيف الأنف، انسداد الأنف (احتقان الأنف)، تهيج الحلق، سيلان الأنف؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الصفاق (النسيج الذي يبطن معظم أعضاء البطن)، والإمساك، وعدم الراحة في المعدة بعد الوجبات (عسر الهضم)، وانتفاخ البطن؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى، احمرار في الجلد، جفاف الجلد، بقع حمراء أو أرجوانية تحت الجلد، زيادة التعرق؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات، وآلام في العضلات، وآلام الظهر والرقبة، وآلام العظام، وتورم المفاصل؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الكِلى أو صعوبة أو ألم عند التبول (عسر البول)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب القضيب التلقائي؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (وذمة)، عدم الرحة في الصدر، شعور بالضعف (الوهن)، ألم في الصدر، ألم في موضع الحقن؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد، وانخفاض في حجم الدّم الذي تشغله خلايا الدّم الحمراء، وانخفاض في بروتين خلايا الدّم الحمراء الذي يحمل الأكسجين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاعراض الجانبية النادرة (قد تؤثر على ما يصل إلى 1 من كل 1000 مريض): </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى بالفطريات، عدوى الرشاشيات، (عدوى المفاصل) التهاب المفاصل البكتيري(عدوى النزلة النزفية)، عدوى اللثة، القوباء، الأمراض البكتيرية المنقولة جنسيّاً؛&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم الجلد (الميلانوما)، اضطراب نخاع العظام؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدمير خلايا الدّم الحمراء (انحلال الدّم) وتكتل الخلايا وعامل تخثر غير طبيعي وتجلط الدّم بشكل غير طبيعي؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية (داء بازدوف)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم، أحلام غير طبيعية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العينين؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاع غير عادي للطعام من المعدة، ألم اللثة؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد و/أو العين (اليرقان)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الجلد، اضطراب لون الجلد؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج عضلات الفم؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول؛&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب الدورة الشهرية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل متعلقة بحقن الدواء: تسرب غير طبيعي للدواء عبر الأنسجة خارج الوريد، إحساس غير طبيعي في موضع الحقن، والشعور بالحرقة أو السخونة؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل متعلق بالتسريب.</p><p dir="RTL"><strong>الإبلاغ عن الأعارض الجانبية </strong></p><p dir="RTL">أبلغ طبيبك أو الصيدلي في حال حدوث أيّ أع ارض جانبية لك، ويشمل ذلك أيّ أع ارض جانبية مُحتملة غير مُدرجة في هذه النشرة. كما يمكنك الإبلاغ عن الأع ارض الجانبية بالاتصال مباشرة بالمركز الوطني للتيقظ والسلامة الدوائية (NPC) &ndash; الهيئة العامة للغذاء والدواء- المملكة العربية السعودية. بالإبلاغ عن الأعراض الجانبية، يُمكنك المُساعدة في توفير مزيد من المعلومات عن سلامة هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدّواء بعيداً عن أنظار ومُتناول الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظه في الثلاجة في درجة حرارة بين( 2<sup>&deg;</sup>م &ndash; 8<sup>&deg;</sup>م)، احفظه داخل العلبة الأصلية لحمايته من الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بِتِجميده.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم برجّ العبوة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق بعد&quot; EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن إخراج قوارير سوليريس وهي داخل العلبة الأصلية من الثلاجة لمرة واحدة لمدة تصل إلى 3 أيّام، في نهاية هذه الفترة، يمكن إعادة المنتج إلى الثلاجة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تخزين المحاليل المُخففة من سوليريس في درجة حرارة بين 2<sup>&deg;</sup>م &ndash; 8<sup>&deg;</sup>م لمدة تصل إلى 24 ساعة قبل حقنِها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من أيّ أدوية عن طريق مياه الصرف الصّحي أو الِنفايات المنزلية. اسأل الصيدلي عن كيفيّة التخلص من الأدوية التي لم تعد بحاجة إليها. تساعد هذه التدابير في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مُحتويات سوليريس </strong></p><p dir="RTL"><strong>تحتوي كل قارورة على المادة الفعالة: </strong></p><p dir="RTL">&nbsp;إيكوليزوماب 300 مجم/30 مل (ما يعادل 10 مجم/مل) <strong>المُكوِّنات الأخرى هي: </strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فوسفات الصوديوم أحادي القاعدة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فوسفات الصوديوم ثنائي القاعدة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>كلوريد الصوديوم</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عديد السوربات 80 (نباتي المصدر)</p><p dir="RTL">&nbsp;<strong>المذيب:</strong> ماء مُخصص للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوليريس هو مُركّز لتحضير محلول للحقن بالتسريب الوريدي، وهو عبارة عن محلول شفاف عديم اللون، لا يحتوي على مواد حافظة، يتوفر في علبة تحتوي على قارورة واحدة سعة 30 مل لاستخدام واحد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>رخصة التّسويق </strong>&nbsp;</p><p dir="RTL">&nbsp;Alexion Europe SAS</p><p dir="RTL">&nbsp;1-15, avenue Edouard Belin</p><p dir="RTL">&nbsp;92500 Rueil-Malmaison</p><p dir="RTL">&nbsp;France</p><p dir="RTL"><strong>الشركة المُصنِّعة </strong></p><p dir="RTL">&nbsp;Alexion Pharma International Operations Unlimited Company</p><p dir="RTL">&nbsp;College Business and Technology Park, Blanchardstown</p><p dir="RTL">&nbsp;Dublin 15, Ireland</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في:  12/2017م 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Soliris 300 mg concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eculizumab is a humanised monoclonal (IgG2/4κ) antibody produced in NS0 cell line by recombinant DNA technology.
One vial of 30 ml contains 300 mg of eculizumab (10 mg/ml).
After dilution, the final concentration of the solution to be infused is 5 mg/ml.
Excipients with known effect: Sodium (5 mmol per vial)
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
Clear, colorless, pH 7.0 solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Soliris is indicated in adults and children for the treatment of:<br />- Paroxysmal nocturnal haemoglobinuria (PNH).<br />Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1).<br />- Atypical haemolytic uremic syndrome (aHUS) (see section 5.1).<br />Soliris is indicated in adults for the treatment of:<br />- Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Soliris must be administered by a healthcare professional and under the supervision of a physician experienced in the management of patients with haematological, renal or neuromuscular disorders.<br />Posology<br />Adult Patients:<br />In Paroxysmal Nocturnal Haemoglobinuria (PNH):<br />The PNH dosing regimen for adult patients (&ge;18 years of age) consists of a 4-week initial phase followed by a maintenance phase:<br /> Initial phase: 600 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion every week for the first 4 weeks.<br />3<br /> Maintenance phase: 900 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion for the fifth week, followed by 900 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion every 14 &plusmn; 2 days (see section 5.1).<br />In atypical Haemolytic Uremic Syndrome (aHUS) and refractory generalized Myasthenia Gravis (gMG):<br />The aHUS and refractory gMG dosing regimen for adult patients (&ge;18 years of age) consists of a 4 week initial phase followed by a maintenance phase:<br />&bull; Initial phase: 900 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion every week for the first 4 weeks.<br />&bull; Maintenance phase: 1,200 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion for the fifth week, followed by 1,200 mg of Soliris administered via a 25 &ndash; 45 minute intravenous infusion every 14 &plusmn; 2 days (see section 5.1).<br />Paediatric patients in PNH and aHUS:<br />Paediatric PNH and aHUS patients with body weight &ge; 40 kg are treated with the adult dosing recommendations, respectively.<br />In paediatric PNH and aHUS patients with body weight below 40 kg, the Soliris dosing regimen consists of:<br />Patient Body Weight<br />Initial Phase<br />Maintenance Phase<br />30 to &lt;40 kg<br />600 mg weekly x 2<br />900 mg at week 3; then 900 mg every 2 weeks<br />20 to &lt;30 kg<br />600 mg weekly x 2<br />600 mg at week 3; then 600 mg every 2 weeks<br />10 to &lt;20 kg<br />600 mg weekly x 1<br />300 mg at week 2; then 300 mg every 2 weeks<br />5 to &lt;10 kg<br />300 mg weekly x 1<br />300 mg at week 2; then 300 mg every 3 weeks<br />Soliris has not been studied in patients with PNH who weigh less than 40kg. The posology of Soliris for PNH patients less than 40kg weight is based on the posology used for patients with aHUS and who weigh less than 40kg.<br />Soliris has not been studied in paediatric patients with refractory gMG.<br />For adult aHUS and refractory gMG patients and paediatric aHUS patients supplemental dosing of Soliris is required in the setting of concomitant PE/PI (plasmapheresis or plasma exchange, or fresh frozen plasma infusion):<br />Type of Plasma Intervention<br />Most Recent Soliris Dose<br />Supplemental Soliris Dose With Each PE/PI Intervention<br />Timing of Supplemental Soliris Dose<br />Plasmapheresis or plasma exchange<br />300 mg<br />300 mg per each plasmapheresis or plasma exchange session<br />Within 60 minutes after each plasmapheresis or plasma exchange<br />&ge;600 mg<br />600 mg per each plasmapheresis or plasma exchange session<br />Fresh frozen plasma infusion<br />&ge;300 mg<br />300 mg per infusion of fresh frozen plasma<br />60 minutes prior to each infusion of fresh frozen plasma<br />Treatment monitoring<br />aHUS patients should be monitored for signs and symptoms of thrombotic microangiopathy (TMA) (see section 4.4 aHUS laboratory monitoring).<br />4<br />Soliris treatment is recommended to continue for the patient&rsquo;s lifetime, unless the discontinuation of Soliris is clinically indicated (see section 4.4).<br />Elderly<br />Soliris may be administered to patients aged 65 years and over. There is no evidence to suggest that any special precautions are needed when older people are treated &ndash; although experience with Soliris in this patient population is still limited.<br />Renal impairment<br />No dose adjustment is required for patients with renal impairment (see section 5.1).<br />Hepatic impairment<br />The safety and efficacy of Soliris have not been studied in patients with hepatic impairment.<br />Method of administration<br />Do not administer as an intravenous push or bolus injection. Soliris should only be administered via intravenous infusion as described below.<br />For instructions on dilution of the medicinal product before administration, see section 6.6.<br />The diluted solution of Soliris should be administered by intravenous infusion over 25 &ndash; 45 minutes in adults and 1-4 hours in paediatric patients via gravity feed, a syringe-type pump, or an infusion pump. It is not necessary to protect the diluted solution of Soliris from light during administration to the patient.<br />Patients should be monitored for one hour following infusion. If an adverse event occurs during the administration of Soliris, the infusion may be slowed or stopped at the discretion of the physician. If the infusion is slowed, the total infusion time may not exceed two hours in adults and adolescents (aged 12 years to under 18 years) and four hours in children aged less than 12 years.<br />Refractory gMG<br />Available data suggest that clinical response is usually achieved by 12 weeks of Soliris treatment. Discontinuation of the therapy should be considered in a patient who shows no evidence of therapeutic benefit by 12 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to eculizumab, murine proteins or to any of the excipients listed in section 6.1.
Soliris therapy must not be initiated in patients (see section 4.4):
- with unresolved Neisseria meningitidis infection
- who are not currently vaccinated against Neisseria meningitidis unless they receive prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Soliris is not expected to affect the aplastic component of anaemia in patients with PNH.<br />Meningococcal Infection<br />Due to its mechanism of action, the use of Soliris increases the patient&rsquo;s susceptibility to meningococcal infection (Neisseria meningitidis). Meningococcal disease due to any serogroup may occur. To reduce the risk of infection, all patients must be vaccinated at least 2 weeks prior to receiving Soliris unless the risk of delaying Soliris therapy outweighs the risks of developing a meningococcal infection. Patients who initiate Soliris treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 and B where available, are recommended in preventing the commonly pathogenic meningococcal serogroups. Patients must receive vaccination according to current national vaccination guidelines for vaccination use.</p><p dir="ltr">Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH, aHUS and refractory gMG, may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH), TMA (aHUS) or MG exacerbation (refractory gMG). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.<br />Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Cases of serious or fatal meningococcal infections have been reported in Soliris-treated patients. All patients should be monitored for early signs of meningococcal infection, evaluated immediately if infection is suspected, and treated with appropriate antibiotics if necessary. Patients should be informed of these signs and symptoms and steps taken to seek medical care immediately. Physicians must discuss the benefits and risks of Soliris therapy with patients and provide them with a patient information brochure and a patient safety card (see Package Leaflet for a description).<br />Other Systemic Infections<br />Due to its mechanism of action, Soliris therapy should be administered with caution to patients with active systemic infections. Patients may have increased susceptibility to infections, especially with encapsulated bacteria. Patients should be provided with information from the Package Leaflet to increase their awareness of potential serious infections and the signs and symptoms of them.<br />Infusion Reactions<br />Administration of Soliris may result in infusion reactions or immunogenicity that could cause allergic or hypersensitivity reactions (including anaphylaxis), though immune system disorders within 48 hours of Soliris administration did not differ from placebo treatment in PNH, aHUS, refractory gMG, and other studies conducted with Soliris. In clinical trials, no PNH, aHUS, or refractory gMG patients experienced an infusion reaction which required discontinuation of Soliris. Soliris administration should be interrupted in all patients experiencing severe infusion reactions and appropriate medical therapy administered.<br />Immunogenicity<br />Infrequent antibody responses have been detected in Soliris-treated patients across all clinical studies. In PNH placebo controlled studies low antibody responses have been reported with a frequency (3.4%) similar to that of placebo (4.8%).<br />In patients with aHUS treated with Soliris, antibodies to Soliris were detected in 3/100 (3%) by the ECL bridging format assay. 1/100 (1%) aHUS patients had low positive values for neutralizing antibodies.<br />In a refractory gMG placebo controlled study, none (0/62) of the Soliris treated patients showed antidrug antibody response during the 26 week active treatment.<br />There has been no observed correlation of antibody development to clinical response or adverse events.<br />Immunization<br />Prior to initiating Soliris therapy, it is recommended that PNH, aHUS, and refractory gMG patients initiate immunizations according to current immunization guidelines. Additionally, all patients must be vaccinated against meningococcal infections at least 2 weeks prior to receiving Soliris unless the risk of delaying Soliris therapy outweighs the risks of developing a meningococcal infection. Patients who initiate Soliris treatment less than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Vaccines against serogroups A, C, Y, W 135 and B where available are recommended in preventing the commonly pathogenic meningococcal serogroups. (see Meningococcal Infection).<br />Patients less than 18 years of age must be vaccinated against Haemophilus influenzae and pneumococcal infections, and strictly need to adhere to the national vaccination recommendations for each age group.</p><p dir="ltr">Vaccination may further activate complement. As a result, patients with complement-mediated diseases, including PNH, aHUS and refractory gMG may experience increased signs and symptoms of their underlying disease, such as haemolysis (PNH), TMA (aHUS) or MG exacerbation (refractory gMG). Therefore, patients should be closely monitored for disease symptoms after recommended vaccination.<br />Anticoagulant therapy<br />Treatment with Soliris should not alter anticoagulant management.<br />Immunosuppressant and anticholinesterase therapies<br />Patients in refractory gMG clinical trials continued treatment with immunosuppressant and anticholinesterase therapies while on Soliris treatment. Withdrawal of immunosuppressant and anticholinesterase therapies during Soliris treatment for refractory gMG was not assessed in the placebo-controlled studies.<br />In the open-label extension trial (Study ECU-MG-302), physicians had the option to adjust background immunosuppressant therapies. In this setting, a decrease of the daily dose of at least 1 immunosuppressant was observed in 47% of patients. The most common reason for change in immunosuppressant therapy was improvement in MG symptoms while on eculizumab treatment. When immunosuppressant and anticholinesterase therapies are decreased or discontinued, patients should be monitored closely for signs of disease exacerbation.<br />PNH Laboratory Monitoring<br />PNH patients should be monitored for signs and symptoms of intravascular haemolysis, including serum lactate dehydrogenase (LDH) levels. PNH patients receiving Soliris therapy should be similarly monitored for intravascular haemolysis by measuring LDH levels, and may require dose adjustment within the recommended 14&plusmn;2 day dosing schedule during the maintenance phase (up to every 12 days).<br />aHUS Laboratory Monitoring<br />aHUS patients receiving Soliris therapy should be monitored for thrombotic microangiopathy by measuring platelet counts, serum LDH and serum creatinine, and may require dose adjustment within the recommended 14&plusmn;2 day dosing schedule during the maintenance phase (up to every 12 days).<br />Treatment Discontinuation for PNH<br />If PNH patients discontinue treatment with Soliris they should be closely monitored for signs and symptoms of serious intravascular haemolysis. Serious haemolysis is identified by serum LDH levels greater than the pre-treatment level, along with any of the following: greater than 25% absolute decrease in PNH clone size (in the absence of dilution due to transfusion) in one week or less; a haemoglobin level of &lt;5 g/dL or a decrease of &gt;4 g/dL in one week or less; angina; change in mental status; a 50% increase in serum creatinine level; or thrombosis. Monitor any patient who discontinues Soliris for at least 8 weeks to detect serious haemolysis and other reactions.<br />If serious haemolysis occurs after Soliris discontinuation, consider the following procedures/treatments: blood transfusion (packed RBCs), or exchange transfusion if the PNH RBCs are &gt;50% of the total RBCs by flow cytometry; anticoagulation; corticosteroids; or reinstitution of Soliris. In PNH clinical studies, 16 patients discontinued the Soliris treatment regimen. Serious haemolysis was not observed.<br />Treatment Discontinuation for aHUS<br />Thrombotic microangiopathy (TMA) complications have been observed as early as 4 weeks and up to 127 weeks following discontinuation of Soliris treatment in some patients. Discontinuation of treatment should only be considered if medically justified.<br />In aHUS clinical studies, 61 patients (21 paediatric patients) discontinued Soliris treatment with a median follow-up period of 24 weeks. Fifteen severe thrombotic microangiopathy (TMA) complications in 12 patients were observed following treatment discontinuation, and 2 severe TMA complications occurred in an additional 2 patients that received a reduced dosing regimen of Soliris outside of the approved dosing regimen (See Section 4.2). Severe TMA complications occurred in 7<br />patients regardless of whether they had an identified genetic mutation, high risk polymorphism or auto-antibody. Additional serious medical complications occurred in these patients including severe worsening of kidney function, disease-related hospitalization and progression to end stage renal disease requiring dialysis. Despite Soliris re-initiation following discontinuation, progression to end stage renal disease occurred in one patient.<br />If aHUS patients discontinue treatment with Soliris, they should be monitored closely for signs and symptoms of severe thrombotic microangiopathy complications. Monitoring may be insufficient to predict or prevent severe thrombotic microangiopathy complications in patients with aHUS after discontinuation of Soliris.<br />Severe thrombotic microangiopathy complications post discontinuation can be identified by (i) any two, or repeated measurement of any one, of the following: a decrease in platelet count of 25% or more as compared to either baseline or to peak platelet count during Soliris treatment; an increase in serum creatinine of 25% or more as compared to baseline or to nadir during Soliris treatment; or, an increase in serum LDH of 25% or more as compared to baseline or to nadir during Soliris treatment; or (ii) any one of the following: a change in mental status or seizures; angina or dyspnoea; or thrombosis.<br />If severe thrombotic microangiopathy complications occur after Soliris discontinuation, consider reinstitution of Soliris treatment, supportive care with PE/PI, or appropriate organ-specific supportive measures including renal support with dialysis, respiratory support with mechanical ventilation or anticoagulation.<br />Treatment discontinuation for refractory gMG:<br />Use of Soliris in refractory gMG treatment has been only studied in the setting of chronic administration. Patients that discontinue Soliris treatment should be carefully monitored for signs and symptoms of deterioration of disease.<br />Educational materials<br />All physicians who intend to prescribe Soliris must ensure they are familiar with the physician&rsquo;s guide to prescribing. Physicians must discuss the benefits and risks of Soliris therapy with patients and provide them with a patient information brochure and a patient safety card.<br />Patients should be instructed that if they develop fever, headache accompanied with fever and/or stiff neck or sensitivity to light, they should immediately seek medical care as these signs may be indicative of meningococcal infection.<br />Excipients<br />This medicinal product contains 5 mmol sodium per vial. It should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No interaction studies have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The use of adequate contraception to prevent pregnancy and for at least 5 months after the last dose of treatment with eculizumab should be considered for women of childbearing potential.<br />Pregnancy<br />There are no well-controlled studies in pregnant women treated with eculizumab. Data on a limited number of pregnancies exposed to eculizumab (less than 300 pregnancy outcomes) indicate there is no increased risk of foetal malformation or foetal-neonatal toxicity. However, due to the lack of well-controlled studies, uncertainties remain. Therefore, an individual risk benefit analysis is recommended before starting and during treatment with eculizumab in pregnant women. Should such a treatment be considered necessary during pregnancy, a close maternal and foetal monitoring according to local guidelines is recommended.<br />8<br />Animal reproduction studies have not been conducted with eculizumab (see section 5.3).<br />Human IgG are known to cross the human placental barrier, and thus eculizumab may potentially cause terminal complement inhibition in the foetal circulation. Therefore, Soliris should be given to a pregnant woman only if clearly needed.<br />Breast-feeding<br />No effects on the breastfed newborn / infant are anticipated as limited data available suggest that eculizumab is not excreted in human breast milk. However, due to the limitations of the available data, the developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for eculizumab and any potential adverse effects on the breastfed child from eculizumab or from the underlying maternal condition.<br />Fertility<br />No specific study of eculizumab on fertility has been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Soliris has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Summary of the safety profile<br />Supportive safety data were obtained from 29 completed and one ongoing clinical studies that included 1,407 patients exposed to eculizumab in ten disease populations, including PNH, aHUS, and refractory gMG. The most common adverse reaction was headache, (occurred mostly in the initial phase), and, of all meningococcal infectionsa the most frequently reported serious adverse reaction was meningococcal sepsis.<br />Tabulated list of adverse reactions<br />Table 1 gives the adverse reactions observed from spontaneous reporting and in eculizumab completed clinical trials, including PNH, aHUS and refractory gMG studies. Adverse reactions reported at a very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) or rare (&ge;1/10,000 to &lt;1/1,000) frequency with eculizumab, are listed by system organ class and preferred term. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.<br />9<br />Table 1: Adverse Reactions reported in 1,407 patients included in overall eculizumab clinical trials, including patients with PNH, aHUS, and refractory gMG as well as from postmarketing experience<br />MedDRA System Organ Class<br />Very Common<br />(&ge;1/10)<br />Common<br />(&ge;1/100 to &lt;1/10)<br />Uncommon<br />(&ge;1/1,000 to &lt;1/100)<br />Rare<br />(&ge;1/10,000 to &lt;1/1,000)<br />Infection and infestations<br />Pneumonia, Upper respiratory tract infection, Nasopharyngitis, Urinary tract infection, Oral Herpes<br />Meningococcal infectiona, Sepsis, Septic shock, Peritonitis, Lower respiratory tract infection, Fungal infection, Viral infection, Bronchitis, Abscess, Cellulitis, Influenza, Gastrointestinal infection, Cystitis, Infection, Sinusitis, Tooth infection<br />Aspergillus infectionb, Arthritis bacterialb, Genitourinary tract gonococcal infection,<br />Haemophilus influenzae infection,<br />Impetigo,<br />Gingivitis<br />Neoplasms benign, malignant and unspecified (including cysts and polyps)<br />Malignant melanoma, Myelodysplastic syndrome<br />Blood and lymphatic system disorders<br />Leukopenia, Anaemia<br />Thrombocytopenia, Lymphopenia<br />Haemolysis*, Abnormal clotting factor, Red blood cell agglutination, Coagulopathy<br />Immune system disorders<br />Anaphylactic reaction, Hypersensitivity<br />Endocrine disorders<br />Basedow&rsquo;s disease<br />Metabolism and nutrition disorders<br />Decreased appetite<br />Psychiatric disorders<br />Insomnia<br />Depression, Anxiety, Mood swings<br />Abnormal dreams, Sleep disorder<br />Nervous system disorders<br />Headache<br />Dizziness, Dysgeusia, Tremor<br />Paraesthesia<br />Syncope<br />Eye disorders<br />Vision blurred<br />Conjunctival irritation<br />Ear and labyrinth disorders<br />Tinnitus, Vertigo<br />Cardiac disorders<br />Palpitation<br />Vascular disorders<br />Hypertension<br />Accelerated hypertension, Hypotension, Hot flush, Vein disorder<br />Haematoma<br />Respiratory, thoracic and mediastinal disorders<br />Cough, Oropharyngeal pain<br />Dyspnoea, Epistaxis, Throat irritation, Nasal congestion, Rhinorrhoea<br />Gastrointestinal disorders<br />Diarrhoea, Vomiting, Nausea, Abdominal pain<br />Constipation, Dyspepsia, Abdominal distension<br />Gastroesophageal reflux disease, Gingival pain<br />Hepatobiliary disorders<br />Jaundice<br />Skin and subcutaneous tissue disorders<br />Rash, Pruritus, Alopecia<br />Urticaria, Erythema, Petechiae, Hyperhidrosis, Dry skin<br />Dermatitis, Skin depigmentation<br />Musculoskeletal and connective tissue<br />Arthralgia, Myalgia, Pain in extremity<br />Muscle spasms, Bone pain, Back pain, Neck<br />Trismus<br />10<br />disorders<br />pain, Joint swelling<br />Renal and urinary disorders<br />Renal impairment, Dysuria<br />Haematuria<br />Reproductive system and breast disorders<br />Spontaneous penile erection, Menstrual disorder<br />General disorders and administration site conditions<br />Pyrexia, Chills, Fatigue, Influenza like illness<br />Oedema, Chest discomfort, Asthenia, Chest pain, Infusion site pain<br />Extravasation, Infusion site paraesthesia, Feeling hot<br />Investigations<br />Alanine aminotransferase increased, Aspartate aminotransferase increased, Gamma-glutamyltransferase increased, Haematocrit decreased, Haemoglobin decreased<br />Coombs test positiveb<br />Injury, poisoning and procedural complication<br />Infusion related reaction<br />*See paragraph Description of selected adverse reactions<br />a=Meningococcal infection includes the following group of PTs: Meningococcal sepsis, Meningococcal meningitis, Neisseria infection; b = Adverse reactions identified in postmarketing reports;<br />Description of selected adverse reactions<br />In all clinical studies, including PNH and aHUS clinical trials, the most serious adverse reaction was meningococcal septicaemia (see section 4.4). No meningococcal infections were reported in completed refractory gMG clinical studies.<br />Antibodies to Soliris were detected in 2% of patients with PNH using an ELISA assay and 3% of patients with aHUS using the ECL bridging format assay. In refractory gMG placebo-controlled studies, no antidrug antibodies were observed. As with all proteins there is a potential for immunogenicity.<br />Cases of haemolysis have been reported in the setting of missed or delayed Soliris dose in PNH clinical trials (see also Section 4.4).<br />Cases of thrombotic microangiopathy complication have been reported in the setting of missed or delayed Soliris dose in aHUS clinical trials (see also Section 4.4).<br />Paediatric population<br />In children and adolescent PNH patients (aged 11 years to less than 18 years) included in the paediatric PNH Study M07-005, the safety profile appeared similar to that observed in adult PNH patients. The most common adverse reaction reported in paediatric patients was headache.<br />In aHUS patients, the safety profile in adolescents (patients aged 12 years to less than 18 years) is consistent with that observed in adults. In paediatric aHUS patients (aged 2 months to less than 18 years) included in the aHUS studies C08-002, C08-003, C09-001r and C10-003, the safety profile appeared similar to that observed in adult aHUS patients. The safety profiles in the different paediatric subsets of age appear similar.<br />Soliris has not been studied in paediatric patients with refractory gMG.<br />Elderly population<br />11<br />No overall differences in safety were reported between elderly (&ge; 65 years) and younger refractory gMG patients (&lt; 65 years) (see section 5.1).<br />Patients with other diseases<br />Safety Data from Other Clinical Studies<br />Supportive safety data were obtained in 13 completed clinical studies that included 856 patients exposed to eculizumab in other disease populations other than PNH, aHUS or refractory gMG. There was an un-vaccinated patient diagnosed with idiopathic membranous glomerulonephropathy who experienced meningococcal meningitis. Adverse reactions reported in patients with disease other than PNH, aHUS, or refractory gMG were similar to those reported in patients with PNH, aHUS, or refractory gMG (see Table 1 above). No specific adverse reactions have emerged from these clinical studies.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No case of overdose has been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Selective immunosuppressants, ATC code: L04AA25<br />Soliris is a recombinant humanised monoclonal IgG2/4k antibody that binds to the human C5 complement protein and inhibits the activation of terminal complement. The Soliris antibody contains human constant regions and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Soliris is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.<br />Soliris is produced in a murine myeloma (NS0 cell line) expression system and purified by affinity and ion exchange chromatography. The bulk drug substance manufacturing process also includes specific viral inactivation and removal steps.<br />Mechanism of action<br />Eculizumab, the active ingredient in Soliris, is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex C5b-9. Eculizumab preserves the early components of complement activation that are essential for opsonization of microorganisms and clearance of immune complexes.<br />In PNH patients, uncontrolled terminal complement activation and the resulting complement-mediated intravascular haemolysis are blocked with Soliris treatment.<br />In most PNH patients, eculizumab serum concentrations of approximately 35 microgram/mL are sufficient for essentially complete inhibition of terminal complement-mediated intravascular haemolysis.<br />In PNH, chronic administration of Soliris resulted in a rapid and sustained reduction in complement-mediated haemolytic activity.<br />12<br />In aHUS patients, uncontrolled terminal complement activation and the resulting complement-mediated thrombotic microangiopathy are blocked with Soliris treatment.<br />All patients treated with Soliris when administered as recommended demonstrated rapid and sustained reduction in terminal complement activity. In all aHUS patients, eculizumab serum concentrations of approximately 50 - 100 microgram/mL are sufficient for essentially complete inhibition of terminal complement activity.<br />In aHUS, chronic administration of Soliris resulted in a rapid and sustained reduction in complement-mediated thrombotic microangiopathy.<br />In refractory gMG patients, uncontrolled terminal complement activation causes membrane attack complex (MAC) dependent lysis and C5a-dependent inflammation at the Neuromuscular Junction (NMJ) leading to failure of neuromuscular transmission. Chronic administration of Soliris results in immediate, complete, and sustained inhibition of terminal complement activity.<br />Clinical efficacy and safety<br />Paroxysmal Nocturnal Haemoglobinuria<br />The safety and efficacy of Soliris in PNH patients with haemolysis were assessed in a randomized, double-blind, placebo-controlled 26 week study (C04-001). PNH patients were also treated with Soliris in a single arm 52 week study (C04-002), and in a long term extension study (E05-001). Patients received meningococcal vaccination prior to receipt of Soliris. In all studies, the dose of eculizumab was 600 mg every 7 &plusmn; 2 days for 4 weeks, followed by 900 mg 7  2 days later, then 900 mg every 14 &plusmn; 2 days for the study duration. Soliris was administered as an intravenous infusion over 25 &ndash; 45 minutes. An observational non-interventional Registry in patients with PNH (M07-001) was also initiated to characterize the natural history of PNH in untreated patients and the clinical outcomes during Soliris treatment.<br />In study C04-001 (TRIUMPH) PNH patients with at least 4 transfusions in the prior 12 months, flow cytometric confirmation of at least 10% PNH cells and platelet counts of at least 100,000/microliter were randomized to either Soliris (n = 43) or placebo (n = 44). Prior to randomization, all patients underwent an initial observation period to confirm the need for RBC transfusion and to identify the haemoglobin concentration (the &quot;set-point&quot;) which would define each patient&rsquo;s haemoglobin stabilization and transfusion outcomes. The haemoglobin set-point was less than or equal to 9 g/dL in patients with symptoms and was less than or equal to 7 g/dL in patients without symptoms. Primary efficacy endpoints were haemoglobin stabilization (patients who maintained a haemoglobin concentration above the haemoglobin set-point and avoid any RBC transfusion for the entire 26 week period) and blood transfusion requirement. Fatigue and health-related quality of life were relevant secondary endpoints. Haemolysis was monitored mainly by the measurement of serum LDH levels, and the proportion of PNH RBCs was monitored by flow cytometry. Patients receiving anticoagulants and systemic corticosteroids at baseline continued these medications. Major baseline characteristics were balanced (see Table 2).<br />In the non-controlled study C04-002 (SHEPHERD), PNH patients with at least one transfusion in the prior 24 months and at least 30,000 platelets/microliter received Soliris over a 52-week period. Concomitant medications included anti-thrombotic agents in 63% of the patients and systemic corticosteroids in 40% of the patients. Baseline characteristics are shown in Table 2.</p><p dir="ltr">Table 2: Patient Demographics and Characteristics in C04-001 and C04-002<br />C04-001<br />C04-002<br />Parameter<br />Placebo N = 44<br />Soliris N = 43<br />Soliris N = 97<br />Mean Age (SD)<br />38.4 (13.4)<br />42.1 (15.5)<br />41.1 (14.4)<br />Gender - Female (%)<br />29 (65.9)<br />23 (53.5)<br />49 (50.5)<br />History of Aplastic Anaemia or MDS (%)<br />12 (27.3)<br />8 (18.7)<br />29 (29.9)<br />Concomitant Anticoagulants (%)<br />20 (45.5)<br />24 (55.8)<br />59 (61)<br />13<br />C04-001<br />C04-002<br />Parameter<br />Placebo N = 44<br />Soliris N = 43<br />Soliris N = 97<br />Concomitant Steroids/Immunosuppressant Treatments (%)<br />16 (36.4)<br />14 (32.6)<br />46 (47.4)<br />Discontinued treatment<br />10<br />2<br />1<br />PRBC in previous 12 months (median (Q1,Q3))<br />17.0 (13.5, 25.0)<br />18.0 (12.0, 24.0)<br />8.0 (4.0, 24.0)<br />Mean Hgb level (g/dL) at setpoint (SD)<br />7.7 (0.75)<br />7.8 (0.79)<br />N/A<br />Pre-treatment LDH levels (median, U/L)<br />2,234.5<br />2,032.0<br />2,051.0<br />Free Haemoglobin at baseline (median, mg/dL)<br />46.2<br />40.5<br />34.9<br />In TRIUMPH, study patients treated with Soliris had significantly reduced (p&lt; 0.001) haemolysis resulting in improvements in anaemia as indicated by increased haemoglobin stabilization and reduced need for RBC transfusions compared to placebo treated patients (see Table 3). These effects were seen among patients within each of the three pre-study RBC transfusion strata (4 - 14 units; 15 - 25 units; &gt; 25 units). After 3 weeks of Soliris treatment, patients reported less fatigue and improved health-related quality of life. Because of the study sample size and duration, the effects of Soliris on thrombotic events could not be determined. In SHEPHERD study, 96 of the 97 enrolled patients completed the study (one patient died following a thrombotic event). A reduction in intravascular haemolysis as measured by serum LDH levels was sustained for the treatment period and resulted in increased transfusion avoidance, a reduced need for RBC transfusion and less fatigue. See Table 3.<br />Table 3: Efficacy Outcomes in C04-001 and C04-002<br />C04-001<br />C04-002*<br />Placebo N = 44<br />Soliris N = 43<br />P &ndash; Value<br />Soliris N = 97<br />P &ndash; Value<br />Percentage of patients with stabilized Haemoglobin levels at end of study<br />0<br />49<br />&lt; 0.001<br />N/A<br />PRBC transfused during treatment (median)<br />10<br />0<br />&lt; 0.001<br />0<br />&lt; 0.001<br />Transfusion Avoidance during treatment (%)<br />0<br />51<br />&lt; 0.001<br />51<br />&lt; 0.001<br />LDH levels at end of study (median, U/L)<br />2,167<br />239<br />&lt; 0.001<br />269<br />&lt; 0.001<br />LDH AUC at end of study (median, U/L x Day)<br />411,822<br />58,587<br />&lt; 0.001<br />-632,264<br />&lt; 0.001<br />Free Haemoglobin at end of study (median, mg/dL)<br />62<br />5<br />&lt; 0.001<br />5<br />&lt; 0.001<br />FACIT-Fatigue (effect size)<br />1.12<br />&lt; 0.001<br />1.14<br />&lt; 0.001<br />* Results from study C04-002 refer to pre- versus post-treatment comparisons.<br />From the 195 patients that originated in C04-001, C04-002 and other initial studies, Soliris-treated PNH patients were enrolled in a long term extension study (E05-001). All patients sustained a reduction in intravascular haemolysis over a total Soliris exposure time ranging from 10 to 54 months. There were fewer thrombotic events with Soliris treatment than during the same period of time prior to treatment. However, this finding was shown in non-controlled clinical trials.<br />The PNH registry (M07-001) was used to evaluate the efficacy of Soliris in PNH patients with no history of RBC transfusion. These patients had high disease activity as defined by elevated haemolysis (LDH &ge;1.5x ULN) and the presence of related clinical symptom(s): fatigue, haemoglobinuria, abdominal pain, shortness of breath (dyspnoea), anaemia (haemoglobin &lt;100 g/L), major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction.<br />14<br />In the PNH Registry, patients treated with Soliris were observed to have a reduction in haemolysis and associated symptoms. At 6 months, patients treated with Soliris with no history of RBC transfusion had significantly (p&lt;0.001) reduced LDH levels (median LDH of 305 U/L; Table 4). Furthermore, 74% of the patients without a history of transfusion and treated with Soliris experienced clinically meaningful improvements in FACIT-Fatigue score (i.e., increase by 4 points or more) and 84% in EORTC fatigue score (i.e., decrease by 10 points or more).<br />Table 4: Efficacy Outcomes (LDH level and FACIT-Fatigue) in Patients with PNH with No History of Transfusion in M07-001<br />M07-001<br />Parameter<br />Soliris<br />No transfusion<br />LDH level at baseline (median , U/L)<br />N=43<br />1447<br />LDH level at 6 months<br />(median, U/L)<br />N=36<br />305<br />FACIT-Fatigue score at baseline<br />(median)<br />N=25<br />32<br />FACIT-Fatigue score at last available assessment (median)<br />N=31<br />44<br />FACIT-Fatigue is measured on a scale of 0-52, with higher values indicating less fatigue<br />Atypical Haemolytic Uremic Syndrome<br />Data from 100 patients in four prospective controlled studies, three in adult and adolescent patients (C08-002A/B C08-003A/B, C10-004) one in paediatric and adolescent patients (C10-003 ) and 30 patients in one retrospective study (C09-001r) were used to evaluate the efficacy of Soliris in the treatment of aHUS.<br />Study C08-002A/B was a prospective, controlled, open-label study which accrued patients in the early phase of aHUS with evidence of clinical thrombotic microangiopathy manifestations with platelet count &le; 150 x 109/L despite PE/PI, and LDH and serum creatinine above upper limits of normal.<br />Study C08-003A/B was a prospective, controlled, open-label study which accrued patients with longer term aHUS without apparent evidence of clinical thrombotic microangiopathy manifestations and receiving chronic PE/PI (&ge;1 PE/PI treatment every two weeks and no more than 3 PE/PI treatments/week for at least 8 weeks before the first dose). Patients in both prospective studies were treated with Soliris for 26 weeks and most patients enrolled into a long-term, open-label extension study. All patients enrolled in both prospective studies had an ADAMTS-13 level above 5%.<br />Patients received meningococcal vaccination prior to receipt of Soliris or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. In all studies, the dose of Soliris in adult and adolescent aHUS patients was 900 mg every 7 &plusmn; 2 days for 4 weeks, followed by 1,200 mg 7  2 days later, then 1,200 mg every 14 &plusmn; 2 days for the study duration. Soliris was administered as an intravenous infusion over 35 minutes. The dosing regimen in paediatric patients and adolescents weighing less than 40 kg was defined based on a pharmacokinetic (PK) simulation that identified the recommended dose and schedule based on body weight (see section 4.2).<br />Primary endpoints included platelet count change from baseline in study C08-002A/B and thrombotic microangiopathy (TMA) event-free status in study C08-003A/B. Additional endpoints included TMA intervention rate, haematologic normalization, complete TMA response, changes in LDH, renal function and quality of life. TMA-event free status was defined as the absence for at least 12 weeks of the following: decrease in platelet count of &gt; 25% from baseline, PE/PI, and new dialysis. TMA<br />15<br />interventions were defined as PE/PI or new dialysis. Haematologic normalization was defined as normalization of platelet counts and LDH levels sustained for &ge;2 consecutive measurements for &ge;4 weeks. Complete TMA response was defined as haematologic normalization and a &ge;25% reduction in serum creatinine sustained in &ge; 2 consecutive measurements for &ge; 4 weeks.<br />Baseline characteristics are shown in Table 5.<br />Table 5: Patient Demographics and Characteristics in C08-002A/B and C08-003A/B<br />Parameter<br />C08-002A/B<br />C08-003A/B<br />Soliris<br />N = 17<br />Soliris<br />N = 20<br />Time from first diagnosis until screening in months, median (min, max)<br />10 (0.26, 236)<br />48 (0.66, 286)<br />Time from current clinical TMA manifestation until screening in months, median (min, max)<br />&lt; 1 (&lt;1, 4)<br />9 (1, 45)<br />Number of PE/PI sessions for current clinical TMA manifestation, median (min, max)<br />17 (2, 37)<br />62 (20, 230)<br />Number of PE/PI sessions in 7 days prior to first dose of eculizumab, median (min, max)<br />6 (0, 7)<br />2 (1, 3)<br />Baseline platelet count (&times; 109/L), mean (SD)<br />109 (32)<br />228 (78)<br />Baseline LDH (U/L), mean (SD)<br />323 (138)<br />223 (70)<br />Patients without identified mutation, n (%)<br />4 (24)<br />6 (30)<br />Patients in aHUS Study C08-002 A/B received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients continued to receive Soliris by enrolling into an extension study. In aHUS Study C08-002A/B, the median duration of Soliris therapy was approximately100 weeks (range: 2 weeks to 145 weeks).<br />A reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of Soliris. Reduction in terminal complement activity was observed in all patients after commencement of Soliris. Table 6 summarizes the efficacy results for aHUS Study C08-002A/B. All rates of efficacy endpoints improved or were maintained through 2 years of treatment. Complete TMA response was maintained by all responders. When treatment was continued for more than 26 weeks, two additional patients achieved and maintained Complete TMA response due to normalization of LDH (1 patient) and a decrease in serum creatinine (2 patients).<br />Renal function, as measured by eGFR, was improved and maintained during Soliris therapy. Four of the five patients who required dialysis at study entry were able to discontinue dialysis for the duration of Soliris treatment, and one patient developed a new dialysis requirement. Patients reported improved health-related quality of life (QoL).<br />In aHUS Study C08-002A/B, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins.<br />Patients in aHUS study C08-003A/B received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients continued to receive Soliris by enrolling into an extension study. In aHUS Study C08-003A/B, the median duration of Soliris therapy was approximately 114 weeks (range: 26 to 129 weeks). Table 6 summarizes the efficacy results for aHUS Study C08-003A/B.<br />In aHUS Study C08-003A/B, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins. Reduction in terminal complement activity was observed in all patients after commencement of Soliris. All rates of efficacy endpoints improved or were maintained through 2 years of treatment. Complete TMA response was maintained by all responders. When treatment was continued for more than 26 weeks, six additional patients achieved and maintained Complete TMA response due to a decrease in serum creatinine. No patient required new dialysis with Soliris. Renal function, as measured by median eGFR, increased during Soliris therapy.<br />16<br />Table 6: Efficacy Outcomes in Prospective aHUS Studies C08-002A/B and C08-003A/B<br />C08-002A/B<br />N=17<br />C08-003A/B<br />N=20<br />At 26 weeks<br />At 2 years1<br />At 26 weeks<br />At 2 years1<br />Normalization of platelet count<br />All patients, n (%)<br />(95% CI)<br />Patients with abnormal baseline, n/n (%)<br />14 (82)<br />(57-96)<br />13/15 (87)<br />15 (88)<br />(64-99)<br />13/15 (87)<br />18 (90)<br />(68-99)<br />1/3 (33)<br />18 (90)<br />(68-99)<br />1/3 (33)<br />TMA event-free status, n (%) (95% CI)<br />15 (88)<br />(64-99)<br />15 (88)<br />(64-99)<br />16 (80)<br />(56-94)<br />19 (95)<br />(75-99)<br />TMA intervention rate<br />Daily pre-eculizumab rate, median (min, max)<br />Daily during-eculizumab rate, median (min, max)<br />P-value<br />0.88<br />(0.04, 1.59)<br />0 (0, 0.31)<br />P&lt;0.0001<br />0.88<br />(0.04, 1.59)<br />0 (0, 0.31)<br />P&lt;0.0001<br />0.23<br />(0.05, 1.09)<br />0<br />P &lt;0.0001<br />0.23<br />(0.05, 1.09)<br />0<br />P&lt;0.0001<br />CKD improvement by &ge;1 stage,<br />n (%) (95% CI)<br />10 (59)<br />(33-82)<br />12 (71)<br />(44-90)<br />7 (35)<br />(15-59)<br />12 (60)<br />(36-81)<br />eGFR change mL/min/1.73 m2: median (range)<br />20 (-1, 98)<br />28 (3, 82)<br />5 (-1, 20)<br />11 (-42, 30)<br />eGFR improvement &ge;15 mL/min/1.73 m2, n (%) (95% CI)<br />8 (47)<br />(23-72)<br />10 (59)<br />(33-82)<br />1 (5)<br />(0-25)<br />8 (40)<br />(19-64)<br />Change in Hgb &gt; 20g/L, n (%) (95% CI)<br />11 (65)<br />(38-86) 2<br />13 (76)<br />(50-93)<br />9 (45)<br />(23-68) 3<br />13 (65)<br />(41-85)<br />Haematologic normalization, n (%) (95% CI)<br />13 (76)<br />(50-93)<br />15 (88)<br />(64-99)<br />18 (90)<br />(68-99)<br />18 (90)<br />(68-99)<br />Complete TMA response, n (%) (95% CI)<br />11(65)<br />(38-86)<br />13(76)<br />(50-93)<br />5 (25)<br />(9-49)<br />11(55)<br />(32-77)<br />1 At data cut off (20 April 2012)<br />2 Study C08-002: 3 patients received ESA which was discontinued after eculizumab initiation<br />3 Study C08-003: 8 patients received ESA which was discontinued in 3 of them during eculizumab therapy<br />aHUS Study C10-004 enrolled 41 patients who displayed signs of thrombotic microangiopathy (TMA). In order to qualify for enrolment, patients were required to have a platelet count &lt; lower limit of normal range (LLN), evidence of haemolysis such as an elevation in serum LDH, and serum creatinine above the upper limits of normal, without the need for chronic dialysis. The median patient age was 35 (range: 18 to 80 years). All patients enrolled in aHUS Study C10-004 had an ADAMTS-13 level above 5%. Fifty-one percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 35 patients received PE/PI prior to eculizumab. Table 7 summarizes the key baseline clinical and disease-related characteristics of patients enrolled in aHUS C10-004.<br />17<br />Table 7: Baseline Characteristics of Patients Enrolled in aHUS Study C10-004<br />Parameter<br />aHUS Study C10-004<br />N = 41<br />Time from aHUS diagnosis to first study dose (months), median ( min, max)<br />0.79 (0.03, 311)<br />Time from current clinical TMA manifestation until first study dose (months), median ( min, max)<br />0.52 (0.03, 19)<br />Baseline platelet count (&times; 109/L), median (, min, max )<br />125 (16, 332)<br />Baseline LDH (U/L), median (, min, max)<br />375 (131, 3318)<br />Baseline eGFR (mL/min/1.73m2), median (min, max)<br />10 (6, 53)<br />Patients in aHUS Study C10-004 received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients elected to continue on chronic dosing.<br />Reduction in terminal complement activity and an increase in platelet count relative to baseline were observed after commencement of Soliris. Soliris reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. In aHUS C10-004, mean (&plusmn;SD) platelet count increased from 119 &plusmn; 66 x109/L at baseline to 200 &plusmn; 84 x109/L by one week; this effect was maintained through 26 weeks (mean platelet count (&plusmn;SD) at week 26: 252 &plusmn; 70 x109/L). Renal function, as measured by eGFR, was improved during Soliris therapy. Twenty of the 24 patients who required dialysis at baseline were able to discontinue dialysis during Soliris treatment. Table 8 summarizes the efficacy results for aHUS study C10-004.<br />Table 8: Efficacy Outcomes in Prospective aHUS Study C10-004<br />Efficacy Parameter<br />aHUS Study C10-004<br />(N = 41) At 26-weeks<br />Change in platelet count through week 26 (109/L)<br />111 (-122, 362)<br />Hematologic Normalization, n (%)<br />Median duration of hematologic normalization, weeks (range) 1<br />36 (88)<br />46 (10, 74)<br />Complete TMA response, n (%) Median duration of complete TMA response, weeks (range) 1<br />23 (56)<br />42 (6, 74)<br />TMA Event-free Status, n (%) 95% CI<br />37 (90)<br />77; 97<br />Daily TMA Intervention Rate, median (range) Before eculizumab On eculizumab treatment<br />0.63 (0, 1.38)<br />0 (0, 0.58)<br />1 Through data cut-off (September 4, 2012), with median duration of Soliris therapy of 50 weeks (range: 13 weeks to 86 weeks).<br />Longer term treatment with Soliris (median 52 weeks ranging from 15 to 126 weeks) was associated with an increased rate of clinically meaningful improvements in adult patients with aHUS. When Soliris treatment was continued for more than 26 weeks, three additional patients (63% of patients in total) achieved Complete TMA response and four additional patients (98% of patients in total)<br />18<br />achieved hematologic normalization. At the last evaluation, 25 of 41 patients (61%) achieved eGFR improvement of &ge; 15 mL/min/1.73 m2 from baseline.<br />Refractory Generalized Myasthenia Gravis<br />Data from 139 patients in two prospective controlled studies (Studies C08-001 and ECU-MG-301), and one open-label extension trial (Study ECU-MG-302) were used to evaluate the efficacy of Soliris in the treatment of patients with refractory gMG.<br />Study ECU-MG-301 (REGAIN) was a 26-week double-blind, randomized, placebo-controlled, multi-center Phase 3 study of Soliris in patients who had failed previous therapies and remain symptomatic. One hundred and eighteen (118) of the 125 (94%) patients completed the 26-week treatment period and 117 (94%) patients subsequently enrolled in Study ECU-MG-302, an open-label, multi-center long-term safety and efficacy extension study in which all patients received Soliris treatment.<br />In Study ECU-MG-301, gMG patients with a positive serologic test for anti-AChR antibodies, MGFA (Myasthenia Gravis Foundation of America) clinical classification class II to IV and MG-ADL total score &ge;6 were randomized to either Soliris (n = 62) or placebo (n = 63). All patients included in the trial were refractory gMG patients and met the following predefined criteria:<br />1) Failed treatment for at least one year with 2 or more immunosuppressant therapies (either in combination or as monotherapy), ie, patients continued to have impairment in activities of daily living despite immunosuppressant therapies<br />OR<br />2) Failed at least one immunosuppressant therapy and required chronic plasma exchange or IVIg to control symptoms, ie, patients require PE or IVIg on a regular basis for the management of muscle weakness at least every 3 months over previous 12 months.<br />Patients received meningococcal vaccination prior to initiating treatment with Soliris or received prophylactic treatment with appropriate antibiotics until 2 weeks after vaccination. In Studies ECU-MG-301 and ECU-MG-302, the dose of Soliris in adult refractory gMG patients was 900 mg every 7 &plusmn; 2 days for 4 weeks, followed by 1200 mg at Week 5&plusmn; 2 days, then 1,200 mg every 14 &plusmn; 2 days for the study duration. Soliris was administered as an intravenous infusion over 35 minutes.<br />Table 9 presents the baseline characteristics of the refractory gMG patients enrolled in Study ECU-MG-301.<br />19<br />Table 9: Patient Demographic and Characteristics in Study ECU-MG-301<br />Soliris (n=62)<br />Placebo (n=63)<br />Age at MG Diagnosis (years),<br />Mean (min, max)<br />38.0 (5.9, 70.8)<br />38.1 (7.7, 78.0)<br />Female, n (%)<br />41 (66.1)<br />41 (65.1)<br />Duration of MG (years),<br />Mean (min, max)<br />9.9 (1.3, 29.7)<br />9.2 (1.0, 33.8)<br />Baseline MG-ADL Score<br />Mean (SD)<br />10.5 (3.06)<br />9.9 (2.58)<br />Median<br />10.0<br />9.0<br />Baseline QMG Score<br />Mean (SD)<br />17.3 (5.10)<br />16.9 (5.56)<br />Median<br />17.0<br />16.0<br />&ge;3 Prior Immunosuppressive Therapies* since diagnosis, n (%)<br />31 (50.0)<br />34 (54.0)<br />Number of patients with prior exacerbations since diagnosis, n (%)<br />46 (74.2)<br />52 (82.5)<br />Number of patients with prior MG crisis since diagnosis, n (%)<br />13 (21.0)<br />10 (15.9)<br />Any prior ventilator support since diagnosis, n (%)<br />15 (24.2)<br />14 (22.2)<br />Any prior intubation since diagnosis (MGFA class V), n (%)<br />11 ( 17.7)<br />9 ( 14.3)<br />* Immunosuppressant&rsquo;s included, but are not limited to, corticosteroids, azathioprine, mycophenolate, methotrexate , cyclosporine, tacrolimus, or cyclophosphamide.<br />The primary endpoint for Study ECU-MG-301 was the change from baseline in the MG Activities of Daily Living Profile (MG-ADL &ndash; a patient reported outcome measure validated in gMG) total score at Week 26. The primary analysis of the MG-ADL was a Worst-Rank ANCOVA with a mean rank of 56.6 for Soliris and 68.3 for placebo, based on 125 study patients (p=0.0698).<br />The key secondary endpoint was the change from baseline in the Quantitative MG Scoring System (QMG &ndash; a physician reported outcome measure validated in gMG) total score at Week 26. The primary analysis of the QMG was a Worst-Rank ANCOVA with a mean rank of 54.7 for Soliris and 70.7 for placebo, based on 125 study patients (p=0.0129).<br />Efficacy outcomes for the pre-specified repeated measures analyses of the primary and secondary endpoints are provided in Table 10.<br />Table 10: ECU-MG-301 Efficacy Outcomes Change from Baseline to Week 26<br />Efficacy Endpoints: Total score change from baseline at Week 26<br />Soliris<br />(n=62)<br />(SEM)<br />Placebo<br />(n=63)<br />(SEM)<br />Soliris change relative to placebo &ndash; LS Mean Difference (95% CI)<br />p-value (using repeated measures analysis)<br />MG-ADL<br />-4.2 (0.49)<br />-2.3(0.48)<br />-1.9<br />(-3.3, -0.6)<br />0.0058<br />QMG<br />-4.6 (0.60)<br />-1.6 (0.59)<br />-3.0<br />(-4.6, -1.3)<br />0.0006<br />MGC<br />-8.1 (0.96)<br />-4.8 (0.94)<br />-3.4<br />(-6.0, -0.7)<br />0.0134<br />MG-QoL-15<br />-12.6 (1.52)<br />-5.4 (1.49)<br />-7.2<br />(-11.5, -3.0)<br />0.0010<br />SEM= Standard Error of the Mean CI= Confidence Interval, MGC= Myasthenia Gravis Composite, MG-QoL15= Myasthenia Gravis Qualtiy of Life 15<br />20<br />In Study ECU-MG-301, a clinical responder in the MG-ADL total score was defined as having at least a 3-point improvement. The proportion of clinical responders at Week 26 with no rescue therapy was 59.7% on Soliris compared with 39.7% on placebo (p=0.0229).<br />In Study ECU-MG-301, a clinical responder in the QMG total score was defined as having at least a 5-point improvement. The proportion of clinical responders at Week 26 with no rescue therapy was 45.2% on Soliris compared with 19% on placebo (p=0.0018).<br />Table 11 presents an overview of the patients reporting clinical deterioration and patients requiring rescue therapy over the 26 weeks.<br />Table 11: Clinical deterioration and rescue therapy in ECU-MG-301<br />Variable<br />Statistic<br />Placebo<br />(N=63)<br />Soliris<br />(N=62)<br />Total number of patients reporting clinical deterioration<br />n (%)<br />15 (23.8)<br />6 (9.7)<br />Total number of patients requiring rescue therapy<br />n (%)<br />12 (19.0)<br />6 (9.7)<br />Of the 125 patients enrolled in ECU-MG-301, 117 patients subsequently were enrolled in a long-term extension study (Study ECU-MG-302), in which all receive Soliris. Patients that were previously treated with Soliris in Study ECU-MG-301 continued to demonstrate a sustained effect of Soliris on all measures (MG-ADL, QMG, MGC and MG-QoL15) over an additional 52 weeks of treatment with Soliris. Figure 1 presents the change from baseline in both MG-ADL (A) and QMG (B) after 26 weeks of treatment in Study ECU-MG-301 and after 52 weeks of treatment in Study ECU-MG-302.<br />Figure 1: Mean changes from baseline in MG-ADL (1A) and QMG (1B) over Studies ECU-MG-301 and ECU-MG-302<br />Twenty-two (22) (17.6%) elderly refractory gMG patients (&gt; 65 years of age) were treated with Soliris in the clinical trials. No substantial differences were seen in safety and efficacy related to age.<br />Paediatric population<br />Paroxysmal Nocturnal Haemoglobinuria<br />A total of 7 PNH paediatric patients, with a median weight of 57.2 kg (range of 48.6 to 69.8 kg) and aged from 11 to 17 years (median age : 15.6 years), received Soliris in study M07-005.<br />-8-6-4-2012348121620264052-8-6-4-20Double BlindOpen Label EculizumabBL1234812162026BLDouble Blind InductionEculizumabPlaceboEcu/ EcuPlacebo / EcuWeeksChange From Baseline MG-ADL Total ScoreChange From Baseline QMG Total ScoreABECU-MG-301ECU-MG-302<br />21<br />Treatment with eculizumab at the proposed dosing regimen in the paediatric population was associated with a reduction of intravascular haemolysis as measured by serum LDH level. It also resulted in a marked decrease or elimination of blood transfusions, and a trend towards an overall improvement in general function. The efficacy of eculizumab treatment in paediatric PNH patients appears to be consistent with that observed in adult PNH patients enrolled in PNH pivotal Studies (C04-001 and C04-002) (Table 3 and 12).<br />Table 12: Efficacy Outcomes in Paediatric PNH Study M07-005<br />P &ndash; Value<br />Mean (SD)<br />Wilcoxon Signed Rank<br />Paired t-test<br />Change from baseline at 12 weeks of LDH Value (U/L)<br />-771 (914)<br />0.0156<br />0.0336<br />LDH AUC (U/L x Day)<br />-60,634 (72,916)<br />0.0156<br />0.0350<br />Change from baseline at 12 weeks in Plasma Free Haemoglobin (mg/dL)<br />-10.3 (21.13)<br />0.2188<br />0.1232<br />Change from baseline Type III RBC clone size (Percent of aberrant cells)<br />1.80 (358.1)<br />Change from baseline at 12 weeks of PedsQLTM4.0 Generic Core scale (patients)<br />10.5 (6.66)<br />0.1250<br />0.0256<br />Change from baseline at 12 weeks of PedsQLTM4.0 Generic Core scale (parents)<br />11.3 (8.5)<br />0.2500<br />0.0737<br />Change from baseline at 12 weeks of PedsQLTM Multidimensional Fatigue (patients)<br />0.8 (21.39)<br />0.6250<br />0.4687<br />Change from baseline at 12 weeks of PedsQLTM Multidimensional Fatigue (parents)<br />5.5 (0.71)<br />0.5000<br />0.0289<br />Atypical Haemolytic Uremic Syndrome<br />A total of 15 paediatric patients (aged 2 months to 12 years) received Soliris in aHUS Study C09-001r. Forty seven percent of patients had an identified complement regulatory factor mutation or auto-antibody. The median time from aHUS diagnosis to first dose of Soliris was 14 months (range &lt;1, 110 months). The median time from current thrombotic microangiopathy manifestation to first dose of Soliris was 1 month (range &lt;1 to 16 months). The median duration of Soliris therapy was 16 weeks (range 4 to 70 weeks) for children &lt; 2 years of age (n=5) and 31 weeks (range 19 to 63 weeks) for children 2 to &lt;12 years of age (n=10).<br />Overall, the efficacy results for these paediatric patients appeared consistent with what was observed in patients enrolled in aHUS pivotal Studies C08-002 and C08-003 (Table 6). No paediatric patient required new dialysis during treatment with Soliris.<br />22<br />Table 13: Efficacy Results in Paediatric Patients Enrolled in aHUS C09-001r<br />Efficacy Parameter<br />&lt;2 years<br />(n=5)<br />2 to &lt;12 years<br />(n=10)<br />&lt;12 years<br />(n=15)<br />Patients with platelet count normalization, n (%)<br />4 (80)<br />10 (100)<br />14 (93)<br />Complete TMA response, n (%)<br />2 (40)<br />5 (50)<br />7 (50)<br />Daily TMA intervention rate, median (range)<br />Before eculizumab<br />On eculizumab treatment<br />1 (0, 2)<br />&lt;1 (0, &lt;1)<br />&lt;1 (0.07, 1.46)<br />0 (0, &lt;1)<br />&lt;1 (0, 2)<br />0 (0, &lt;1)<br />Patients with eGFR improvement &ge;15 mL/min/1.73 m2, n (%)<br />2 (40)<br />6 (60)<br />8 (53)<br />In paediatric patients with shorter duration of current severe clinical thrombotic microangiopathy (TMA) manifestation prior to eculizumab, there was TMA control and improvement of renal function with eculizumab treatment (Table 13).<br />In paediatric patients with longer duration of current severe clinical TMA manifestation prior to eculizumab, there was TMA control with eculizumab treatment. However, renal function was not changed due to prior irreversible kidney damage (Table 14).<br />Table 14: Efficacy Outcomes in Paediatric Patients in Study C09-001r according to duration of current severe clinical thrombotic microangiopathy (TMA) manifestation<br />Duration of current severe clinical TMA manifestation<br />&lt; 2 months N=10 (%)<br />&gt;2 months N=5 (%)<br />Platelet count normalization<br />9 (90)<br />5 (100)<br />TMA event-free status<br />8 (80)<br />3 (60)<br />Complete TMA response<br />7 (70)<br />0<br />eGFR improvement &ge; 15 mL/min/1.73m2<br />7 (70)<br />0*<br />*One patient achieved eGFR improvement after renal transplant<br />A total of 22 paediatric and adolescents patients (aged 5 months to 17 years) received Soliris in aHUS Study C10-003.<br />In Study C10-003, patients who enrolled in the study were required to have a platelet count &lt; lower limit of normal range (LLN), evidence of haemolysis such as an elevation in serum LDH above the upper limits of normal and serum creatinine level &ge;97 percentile for age without the need for chronic dialysis. The median patient age was 6.5 years (range: 5 months to 17 years). Patients enrolled in aHUS C10-003 had an ADAMTS-13 level above 5%. Fifty percent of patients had an identified complement regulatory factor mutation or auto-antibody. A total of 10 patients received PE/PI prior to eculizumab. Table 15 summarizes the key baseline clinical and disease-related characteristics of patients enrolled in aHUS Study C10-003.<br />23<br />Table 15: Baseline Characteristics of Paediatric and Adolescents Patients Enrolled in aHUS Study C10-003<br />Parameter<br />1 month to &lt;12 years<br />(N = 18)<br />All Patients<br />(N = 22)<br />Time from aHUS diagnosis until first study dose (months) median (min, max )<br />0.51 (0.03, 58)<br />0.56 (0.03,191)<br />Time from current clinical TMA manifestation until first study dose (months), median ( min, max)<br />0.23 (0.03, 4)<br />0.20 (0.03, 4)<br />Baseline platelet count (x 109/L), median ( min, max)<br />110 (19, 146)<br />91 (19,146)<br />Baseline LDH (U/L) median (min, max )<br />1510 (282, 7164)<br />1244 (282, 7164)<br />Baseline eGFR (mL/min/1.73 m2 ), median (min, max)<br />22 (10, 105)<br />22 (10, 105)<br />Patients in aHUS C10-003 received Soliris for a minimum of 26 weeks. After completion of the initial 26-week treatment period, most patients elected to continue on chronic dosing. Reduction in terminal complement activity was observed in all patients after commencement of Soliris. Soliris reduced signs of complement-mediated TMA activity, as shown by an increase in mean platelet counts from baseline to 26 weeks. The mean (&plusmn;SD) platelet count increased from 88 &plusmn; 42 x109/L at baseline to 281 &plusmn; 123 x109/L by one week; this effect was maintained through 26 weeks (mean platelet count (&plusmn;SD) at week 26: 293 &plusmn; 106 x109/L). Renal function, as measured by eGFR, was improved during Soliris therapy. Nine of the 11 patients who required dialysis at baseline no longer required dialysis after Study Day 15 of eculizumab treatment. Responses were similar across all ages from 5 months to 17 years of age. In aHUS C10-003, responses to Soliris were similar in patients with and without identified mutations in genes encoding complement regulatory factor proteins or auto-antibodies to factor H.<br />Table 16 summarizes the efficacy results for aHUS C10-003.<br />Table 16: Efficacy Outcomes in Prospective aHUS Study C10-003<br />Efficacy Parameter<br />1 month to &lt;12 years<br />(N = 18)<br />At 26-weeks<br />All Patients<br />(N = 22)<br />At 26-weeks<br />Complete Hematologic Normalization, n (%)<br />Median Duration of complete hematologic normalization, weeks (range) 1<br />14 (78)<br />35 (13, 78)<br />18 (82)<br />35 (13, 78)<br />Complete TMA response, n (%)<br />Median Duration of complete TMA response, weeks (range)1<br />11 (61)<br />40 (13, 78)<br />14 (64)<br />37 (13, 78)<br />TMA Event-Free Status, n (%)<br />95% CI<br />17 (94)<br />NA<br />21 (96)<br />77; 99<br />Daily TMA Intervention rate, median (range)<br />Before eculizumab treatment, median<br />On eculizumab treatment, median<br />NA<br />NA<br />0.4 (0, 1.7)<br />0 (0, 1.01)<br />eGFR improvement &ge;15 mL/min/ 1.73&bull;m2, n (%)<br />16 (89)<br />19 (86)<br />24<br />Efficacy Parameter<br />1 month to &lt;12 years<br />(N = 18)<br />At 26-weeks<br />All Patients<br />(N = 22)<br />At 26-weeks<br />Change in eGFR ( &ge;15 mL/min/1.73&bull;m2) at 26 weeks, median (range)<br />64 (0,146)<br />58 (0, 146)<br />CKD improvement by &ge;1 stage, n (%)<br />14/16 (88)<br />17/20 (85)<br />PE/PI Event-Free Status, n (%)<br />New Dialysis Event-Free Status, n (%)<br />95% CI<br />16 (89)<br />18 (100)<br />NA<br />20 (91)<br />22 (100)<br />85;100<br />1 Through data cut-off (October 12, 2012), with median duration of Soliris therapy of 44 weeks (range: 1 dose to 88 weeks).<br />Longer term treatment with Soliris (median 55 weeks ranging from 1day to 107 weeks) was associated with an increased rate of clinically meaningful improvements in paediatric and adolescent patients with aHUS. When Soliris treatment was continued for more than 26 weeks, one additional patient (68% of patients in total) achieved Complete TMA Response and two additional patients (91% of patients in total) achieved hematologic normalization. At the last evaluation, 19 of 22 patients (86%) achieved eGFR improvement of &ge; 15 mL/min/1.73 m2 from baseline. No patient required new dialysis with Soliris.<br />Refractory Generalized Myasthenia Gravis<br />Soliris has not been evaluated in paediatric patients with refractory gMG.<br />The European Medicines Agency has deferred the obligation to submit the results of studies with Soliris in one or more subsets of the paediatric population in the treatment of refractory gMG (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacokinetics and Drug Metabolism<br />Biotransformation<br />Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolized by lysosomal enzymes to small peptides and amino acids.<br />Elimination<br />No specific studies have been performed to evaluate the hepatic, renal, lung, or gastrointestinal routes of excretion/elimination for Soliris. In normal kidneys, antibodies are not excreted and are excluded from filtration by their size.<br />Pharmacokinetic Parameters<br />In 40 patients with PNH, a 1-compartmental model was used to estimate pharmacokinetic parameters after multiple doses. Mean clearance was 0.31  0.12 mL/hr/kg, mean volume of distribution was 110.3  17.9 mL/kg, and mean elimination half-life was 11.3  3.4 days. Based on these data, the onset of steady state is predicted to be approximately 49 &ndash; 56 days.<br />In PNH patients, pharmacodynamic activity correlates directly with eculizumab serum concentrations and maintenance of trough levels above  35 microgram/mL results in essentially complete blockade of haemolytic activity in the majority of PNH patients.<br />A second population PK analysis with a standard 1 compartmental model was conducted on the multiple dose PK data from 37 aHUS patients receiving the recommended Soliris regimen in studies C08-002A/B and C08-003A/B. In this model, the clearance of Soliris for a typical aHUS patient<br />25<br />weighing 70 kg was 0.0139 L/hr and the volume of distribution was 5.6 L. The elimination half-life was 297 h (approximately 12.4 days).<br />The second population PK model was applied to the multiple dose PK data from 22 paediatric aHUS patients receiving the recommended Soliris regimen in aHUS C10-003. The clearance and volume of distribution of Soliris are weight dependent, which forms the basis for a weight categorical based dose regimen in paediatric patients (see section 4.2). Clearance values of Soliris in paediatric aHUS patients were 10.4, 5.3, and 2.2 mL/hr with body weight of 70, 30, and 10 kg, respectively; and the corresponding volume of distribution values were 5.23, 2.76, and 1.21 L, respectively. The corresponding elimination half-life remained almost unchanged within a range of 349 to 378 h (approximately 14.5 to 15.8 days).<br />The clearance and half-life of eculizumab were also evaluated during plasma exchange interventions. Plasma exchange resulted in an approximately 50% decline in eculizumab concentrations following a 1 hour intervention and the elimination half-life of eculizumab was reduced to 1.3 hours. Supplemental dosing is recommended when Soliris is administered to aHUS patients receiving plasma infusion or exchange (see section 4.2).<br />All aHUS patients treated with Soliris when administered as recommended demonstrated rapid and sustained reduction in terminal complement activity. In aHUS patients, pharmacodynamic activity correlates directly with eculizumab serum concentrations and maintenance of trough levels of approximately 50-100 microgram/ml results in essentially complete blockade of terminal complement activity in all aHUS patients.<br />PK parameters observed in the refractory gMG population are consistent with what has been observed in PNH and aHUS populations.<br />Pharmacodynamic activity measured by free C5 concentrations of &lt;0.5 ug/mL, is correlated with essentially complete blockade of terminal complement activity in PNH, aHUS, and refractory gMG patients.<br />Special Populations<br />PNH and refractory gMG<br />Dedicated studies have not been conducted to evaluate the pharmacokinetics of Soliris in special PNH or refractory gMG patient populations identified by gender, race, age (geriatric), or the presence of renal or hepatic impairment.<br />Paediatric population<br />The pharmacokinetics of eculizumab was evaluated in Study M07-005 including 7 PNH paediatric patients (aged from 11 to less than 18 years).<br />Weight was a significant covariate resulting in a lower eculizumab clearance 0.0105 L/h in the adolescent patients. Dosing for paediatric patients &lt;40 kg is based on paediatric patients with aHUS.<br />aHUS<br />The pharmacokinetics of Soliris have been studied in aHUS patients with a range of renal impairment and age. There have been no observed differences in pharmacokinetic parameters noted in these subpopulations of aHUS patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The specificity of eculizumab for C5 in human serum was evaluated in two in vitro studies.<br />The tissue cross-reactivity of eculizumab was evaluated by assessing binding to a panel of 38 human tissues. C5 expression in the human tissue panel examined in this study is consistent with published reports of C5 expression, as C5 has been reported in smooth muscle, striated muscle, and renal proximal tubular epithelium. No unexpected tissue cross-reactivity was observed.<br />26<br />Animal reproduction studies have not been conducted with eculizumab due to lack of pharmacologic activity in non-human species.<br />In a 26 week toxicity study performed in mice with a surrogate antibody directed against murine C5, treatment did not affect any of the toxicity parameters examined. Haemolytic activity during the course of the study was effectively blocked in both female and male mice.<br />No clear treatment-related effects or adverse effects were observed in reproductive toxicology studies in mice with a surrogate terminal complement inhibitory antibody, which was utilized to assess the reproductive safety of C5 blockade. These studies included assessment of fertility and early embryonic development, developmental toxicity, and pre and post-natal development.<br />When maternal exposure to the antibody occurred during organogenesis, two cases of retinal dysplasia and one case of umbilical hernia were observed among 230 offspring born to mothers exposed to the higher antibody dose (approximately 4 times the maximum recommended human Soliris dose, based on a body weight comparison); however, the exposure did not increase foetal loss or neonatal death.<br />No animal studies have been conducted to evaluate the genotoxic and carcinogenic potential of eculizumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium phosphate, monobasic<br />Sodium phosphate, dibasic<br />Sodium chloride<br />Polysorbate 80<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months.
After dilution, the medicinal product should be used immediately. However, chemical and physical stability has been demonstrated for 24 hours at 2°C – 8°C.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze. Do not shake.Store in the original package in order to protect from light. Soliris vials in the original package may be removed from refrigerated storage for only one single period of up to 3 days. At the end of this period the product can be put back in the refrigerator. For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">30 ml of concentrate in a vial (Type I glass) with a stopper (butyl, siliconised), and a seal (aluminium) with flip-off cap (polypropylene).<br />Pack size of one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Prior to administration, the Soliris solution should be visually inspected for particulate matter and discolouration.<br />Instructions:<br />Reconstitution and dilution should be performed in accordance with good practices rules, particularly for the respect of asepsis.<br />Withdraw the total amount of Soliris from the vial(s) using a sterile syringe.<br />Transfer the recommended dose to an infusion bag.<br />Dilute Soliris to a final concentration of 5 mg/ml by addition to the infusion bag using sodium chloride 9 mg/ml (0.9%) solution for injection, sodium chloride 4.5 mg/ml (0.45%) solution for injection, or 5% dextrose in water, as the diluent.<br />The final volume of a 5 mg/ml diluted solution is 60 ml for 300 mg doses, 120 ml for 600 mg doses, 180 ml for 900 mg doses and 240 ml for 1,200 mg doses. The solution should be clear and colourless.<br />Gently agitate the infusion bag containing the diluted solution to ensure thorough mixing of the product and diluent.<br />The diluted solution should be allowed to warm to room temperature prior to administration by exposure to ambient air.<br />Discard any unused portion left in a vial, as the product contains no preservatives.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Alexion Europe SAS
1-15, avenue Edouard Belin
92500 Rueil-Malmaison
FRANCE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date: 14/12/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>